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Escherichia coli(E.coli) belongs to the Enterobacteriaceae family of gram negative rods. It is the most 
common cause for bacterial sepsis. According to NORM (Norwegian system for surveillance of 
antibiotic resistance in microbes);  E.coli is the main pathogen found in blood samples from humans 
submitted to Norwegian microbial laboratories (page 49 NORM report 2008)(1).  E.coli is also the 
most common cause of human urinary tract infections (The Journal of the Norwegian Medical 
Association) (2).   
Empiric treatment for sepsis and urosepsis in Norway is betalactam antibiotics in combination with 
aminoglycosides(3). In case of allergy, patients with urosepsis are treated with quinolones and 
aminoglycosides(4). There is concern related to recent years development of resistance against 
gentamicin (aminoglycoside) and ciprofloxacin (quinolone) among E.coli strains (page 52 NORM 
report 2008) (1). 
This work was initiated as a first step to identify the most common mechanisms for aminoglycoside 
resistance in Enterobacteriaceae collected in western Norway. The focus for this work was to 
characterize antibiotic resistance and detect the presence of the genes encoding two aminoglycoside 
modifying enzymes. The genes chosen encodes two enzymes from the group aminoglycoside 
acetyltransferases (AAC`s); aac(6`)-Ib and aac(3)-IIc (aacC2). 
The use of ciprofloxacin has increased markedly during the past few years. Recent studies have 
reported a variant of AAC(6`)-Ib characterized by two amino acid changes, Trp102Arg and 
Asp179Tyr. This variant called AAC(6`)-Ib-cr inflicts ciprofloxacin resistance in addition to 
aminoglycoside resistance. We suspected that increased use of ciprofloxacin could cause selection of 
isolates resistant to aminoglycosides by selecting the isolates that possess AAC(6`)-Ib-cr. We decided 
to examine the prevalence of aac(6`)-Ib-cr in isolates of Enterobaceriaceae resistant aminoglycosides, 















A   Adenine 
AAC   Aminoglycoside acetyltransferases 
AAC(6`)-Ib  Aminoglycoside acetyltransferase(6`)-Ib   
AAC(6`)-Ib-cr  Aminoglycoside acetyltransferase(6`)-Ib-ciprofloxacin variant 
aac(6`)-Ib  The gene encoding AAC(6`)-Ib 
aac(6`)-Ib-cr  The gene encoding AAC(6`)-Ib-cr 
AAC(3)-II  Aminoglycoside acetyltransferase(3`)-II 
aac(3)-II  The gene encoding AAC(3`)-II 
AFA   Norwegian workgroup for questions related to antibiotics 
AK   Amikacin 
AmpC   Genes encoding extended spectrum beta lactamases 
Arg   Arginine      
Asp   Aspartic acid 
BLAST   Basic Local Alignment tool 
C   Cytosine 
CTX-M   Genes encoding beta lactamases with extended spectra 
DDD   Defined Daily Dose 
DNA    Deoxyribonucleic acid 
E.coli   Eschericia coli 
ESBL   Extended spectrum beta-lactamase 
EUCAST  The European comity on antibiotic susceptibility testing 
G   Guanine 
GM   Gentamicin 
gyrA   Gene encoding the enzyme; DNA gyrase 
gyrB   Gene encoding the enzyme; DNA gyrase 
I   Intermediate resistant 
K-res   Norwegian center for expertise for antibiotic susceptibility testing 
KM   Kanamycin 
MIC   Minimum inhibitory concentration 
NC    Netilmicin 
NCBI   Genome database of the National Center for Biotechnology Information 
NORM    Norwegian system for surveillance of antibiotic resistance in microbes  
(Norsk overvåkningssystem for antibiotikaresistens hos mikrober) 
NorPD   Norwegian prescription data base 
parC   Gene encoding the enzyme; topoisomerase IV 
pare   Gene encoding the enzyme; topoisomerase IV 
PCR     Polymerase chain reaction 
R   Resistant 
RNA   Ribonucleic acid 
S   Sensitive / Susceptible 
SHV   Genes encoding beta lactamases ( some with extended spectra) 
SM   Streptomycin 
SNP   Single Nucleotide Polymorphism 
ssp    Species 
T   Thymine 
TEM   Genes encoding beta lactamases ( some with extended spectra) 
TM    Tobramycin 
Trp   Tryphtophane 
Tyr   Tyrosine 







Agar A gelatinous material derived from certain marine algae. It is used as a base 
for bacterial culture media 
Antimetabolites A substance bearing a close structural resemblance to one required for 
normal physiological functioning, and exerting its effect by interfering with 
the utilization of the essential metabolite.  
Chromosome The genetic element in the cell that contains genes whose products is 
involved in essential cellular functions. 
Efflux pumps An active transport system for the removal of some antibiotics 
Eukaryotic cell Structurally large and complex cells containing membrane-enclosed 
organelles. Algae, fungi and protozoa, plants and animals are eukaryotes. 
Genome Total complement of genes in a cell; includes chromosomes and other genetic 
elements like plasmids, transposable elements etc. 
Gram negative cell A prokaryotic cell whose cell wall contains relatively little peptidoglycan but 
has an outer membrane composed of lipopolysaccharide, lipoprotein, and 
other complex macromolecules  
Integrons A set of genes and other DNA sequences that enable plasmids to capture 
genes from bacteriophages and other plasmids 
Lethality   Causing death, Fetality 
Metabolites   A substance produced by metabolism 
Moiety    Portion, half 
Morbidity Incidence and prevalence of disease in a population, including both fatal and 
non fatal cases 
Mutation   An inheritable change in the base sequence of the genome of an organism 
Nephrotoxicity   Toxic to the kidneys 
Nucleic acid   A polymer of nucleotides 
Ototoxicity   Damaging to the hearing ability 
Parenterally   Administered not through mouth. (intra venous, sub cutan etc.) 
Pathogen    An organism, usually microorganism, that causes disease 
Permeability   Being permeable, being porous, substances can sieve thorugh  
Pharmacokinetics The study of the process by which a drug is absorbed, distributed, 
metabolized, and eliminated by the body 
Pharmacodynamics  The study of the action or effects of drugs on living organisms 
Phenotype   The observable characteristics of an organism 
Plasmid Genetic elements that exist and replicate separately from the chromosome. 
They contain genes beneficial for the organism, but not genes for essential 
cellular functions. 
Prevalence   Measurement of frequnecy 
Prokaryotic Structurally “simpler” cells lacking membrane-enclosed organelles. Bacteria 
and Arcaha are prokaryotes.   
Proofreading The 3`-5`-exonuclease activity possessed by some DNA polymerases which 
enables the enzyme to replace a misincorporated nucleotide 
Ribosome   “The cell`s protein-synthesizing factory” 
Rod    Describes the shape of the bacteria (curvy comma shaped) 
Sepsis / Septicaemia  Infection of the blood stream by bacteria 
Single Nucleotide Polymorphism A point mutation that is carried by some individuals of a population 
Template The polynucleotide that is copied during a strand synthesis reaction catalyzed 
by DNA or RNA polymerase 
Translation The synthesis of protein using the genetic information in messenger RNA as 
a template 
Transposon A type of transposable element that, in addition to genes involved in 
transposition, carries other genes; often genes conferring selectable 
phenotypes such as antibiotic resistance. 










The discovery of antimicrobial agents has improved public health significantly. When the first 
sulphonamides came on the market in the middle of the 1930`s, they started a new era in the treatment 
of infectious diseases such as pneumonia, urinary tract infections and meningitis. These infectious 
diseases were previously associated with high lethality and long lasting morbidity. The most 
significant breakthrough in the development of antibiotics was probably the discovery and 
manufacture of Penicillin. Many different types of antimicrobials were marketed in the years to 
follow. Unfortunately not many years passed before antimicrobial resistance developed as a significant 
clinical problem. Resistance leads to loss off efficacy of antimicrobial agents. The continued 
development of new or improved agents has allowed us to maintain efficient antimicrobial therapy, 
but antibiotic resistance remains a challenge. Development of new agents is associated with increasing 
cost and effort(5). With few new agents coming on the marked, attenuating antibiotic resistance is of 
vital importance.  
Use and misuse of antimicrobials is the main cause of antibiotic resistance development in microbes. 
New measures like prescription guidelines have been published to ensure correct use of antimicrobial 
agents. Surveillance of both antimicrobial resistance development and antimicrobial usage give 
valuable information for the prescription guidelines. Such surveillance data also makes it possible to 
evaluate any measures made towards the correct use of antimicrobial agents. In addition, this 
information can be used to increase our understanding on the relationship between the use of 
antimicrobial agents and resistance development.   
Surveillance of antimicrobial resistant strains in Norway is performed by NORM (Norwegian system 
for surveillance of antibiotic resistance in microbes) since 1999.  Data published in the NORM report 
of 2008 shows that E.coli, which belong to the family of Enterobacteriaceae is the predominant 
species isolated from blood cultures. (1) (figure 30, page 50) E.coli is also the predominant species 
causing urinary tract infections (The Journal of the Norwegian Medical Association) (2).  E.coli has 
been reported to show a steadily increasing gentamicin resistance during 2004-2007 though a slight 
decrease was reported in 2008.There is also a contemporary increase in resistance against 
ciprofloxacin (fluoroquinolone) from 2004-2008 among E.coli(1).  
In Norway, a combination of a penicillin and an aminoglycoside is the emperical treatment for 
septicaemia and if urosepsis (sepsis secondary to urinary tract infections) is suspected, the initial 
therapy is with either ciprofloxacin or cephalosporin, until the microorganism has been identified and 
possible until antimicrobial sensitivity is determined(6). Increasing resistance of E.coli for 
aminoglycosides or ciprofloxacin impose a serious threat to this standard treatment. The cause of the 
increasing resistance is disputed as few studies on this topic have been published. Recent reports 
suggest an association between the use of ciprofloxacin and development of aminoglycoside 
resistance, based on the identification of a variant of the aminoglycoside modifying enzyme AAC(6`)-
Ib termed AAC(6`)-Ib-cr, which confers resistance to both aminoglycosides and fluoroquinolones. 
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These studies additionally report correlations between the presence of the gene for this enzyme and the 
presence of other plasmid mediated resistance genes, thus conferring multi-resistance. 
It is important that the national guidelines for use of antimicrobial agents are evaluated and modified 
as new insight into antibiotic resistance is gained. There is a need for research related aminoglycoside 
resistance in Norway to learn about mechanisms which has caused the increasing resistance during the 
past years.  The relevance of AAC(6`)-Ib-cr as the cause for increasing aminoglycoside resistance is 
not studied in Norwegian isolates. In this study, we wanted to look into this possibility by screening 
for the gene aac(6`)-Ib-cr in Norwegian clinical isolates and relating the results to their susceptibility 
patterns for aminoglycosides and ciprofloxacin. Our hypothesis is that there could be a strong 
association between the increased use of ciprofloxacin and selection of combined aminoglycoside and 
ciprofloxacin resistance due to the presence of the gene for this enzyme. In addition to AAC(6`)-Ib 
which is reported to be the most prevalent of all aminoglycoside acetyltransferases (AACs) (7), we 
looked for the presence of a second aminoglycoside acetyltransferase AAC(3`)-IIc (also known as 
aacC2). AAC(3)s  is reported to be the second largest group of aminoglycoside acetyltransferases 























Antibiotics are microbial metabolites or synthetic analogs inspired by them that, in small doses, inhibit 
the growth and survival of microorganisms without causing serious toxicity to the host. Based the 
original definition all antibiotics are natural products or derivates based on them. Chemical 
modifications to the original structure have given rise to substances with broader antimicrobial 
spectrum, greater potency, lesser toxicity, more convenient administrations, etc. When fully synthetic 
agents for the use against infections were developed, they were classified as chemotherapeutic agents. 
A general term for both antibiotics and chemotherapeutic agents used against microbes is 
antimicrobial agents; this term also includes agents against viral, fungal and protozoan infections. 
When speaking of drugs used only against bacterial infection, the term antibiotic is now commonly 
used for antimicrobial agents of natural as well as synthetic origin. 
The first truly effective antimicrobial agent was a chemotherapeutic agent which dates back as far as 
in the mid 1930`s. The trade name was Prontosil, and it belongs to the group of sufonamides. The first 
antibiotic came to use in the 1940`s; this was penicillin belonging to the group of beta-lactam 
antibiotics. In the years to follow many new agents were discovered or synthesized contributing to the 
treatment of infectious diseases.  
Figure 1.1: Timeline of discovered antimicrobial agents. (Figure adopted from:(8)) 
 
 
Antibiotics are, because of availability, familiarity, generally low cost and relative safety, among the 
most misused of all medication(9). Misuse and consequent resistance development threatens their 
continued efficacy. Unfortunately we can no longer depend on discovery of new agents to keep the 
infectional diseases under control. Restriction and prudent use of these agents is critical for the sake of 








Bacteria have prokaryotic cell structure which is distinct from human cells. This facilitates design of 
drugs ensuring bacterial specificity without significant harm to the host cell. There are four major sites 
in the bacterial cell and aspects of its metabolic pathway that are sufficiently different from human 
cells to allow antimicrobial targeting. 
 
• Cell wall (disrupts synthesis of cell wall). 
• The bacterial ribosome (disrupts protein synthesis). 
• The nucleic acid synthetic pathway  
• The cell membrane (disrupts cell membrane). 




1.2.3 Antimicrobial groups 
 
Table 1.1: Site of action for different antibiotics divided: 
Cell wall The bacterial 
ribosome 






























 1.2.3 Antibacterial efficacy 
 
Antibiotics are classified clinically as bactericidal or bacteriostatic depending on their ability to kill 
microorganisms or prevent them from multiplying, when given in normal therapeutic dosages. 
Bactericidal drugs kill microorganisms. Bacteriostatic drugs will not kill the microorganisms; they are 
given in concentrations to interrupt the rapid growth of the organisms and are dependent on the host 
immune system be rid of the bacteria(10). 
The efficacy of antibiotics depends on the microbe’s sensitivity towards it and the concentration of the 
drug. Minimum inhibitory concentration (MIC) is a useful indicator for treatment. This is the lowest 
concentration of the drug that under certain conditions inhibit growth of the bacteria. Low MIC values 
are generally consistent with effective drugs, but pharmacokinetic and pharmacodynamic 
considerations play an important part in determining the dosage and dosage interval.  
MIC-values are used to characterize the bacteria as sensitive (S), intermediate (I) or resistant (R) 
against the antibiotic according to the SIR system(11). AFA (Norwegian workgroup for questions 
related to antibiotics) annually updates guidelines for such classification, in collaboration with 
EUCAST (The European Committee on Antimicrobial Susceptibility Testing). These guidelines 
provide threshold MIC values used to identify a certain strain as Sensitive, Inetermediate or Resistant. 
 
Figure 1.2: Antibiotic sensitivity as applied in the SIR-system 
S (Sensitive) I (Intermediate) R (Resistant) 
The bacterial isolate is sensitive 
for the drug. Clinical effect of 
the drug is expected with 
normal dosage, if the drug 
reaches infection focus. 
The bacterial isolate is 
intermediate between sensitive 
and resistant. With increased 
dosage it might be possible to 
have clinical effect of the drug. 
Clinical effect of the drug is not 
likely due to the bacterial 




There are various methods in use to determine bacterial sensitivity towards an antibiotic. The broth 
dilution method is the reference method but it is rarely used in routine laboratories; in this method a 
standardized amount of bacteria is grown in a fluid media or on agar media containing different 
concentrations of the specific agent. Usually the concentrations are 2-folds dilution which span over 
all concentrations clinically relevant for the agent. After overnight incubation at 35-37°C the minimum 
inhibitory concentration (MIC value) can be read as the lowest concentration of the drug that produces 
no visual growth. A similar approach, but easier in application is the E-test method. Assessing the 
susceptibility according to the size of the zones of bacterial inhibition around discs containing specific 






Disc diffusion method: 
The disc diffusion method for antibiotic susceptibility testing is called the Kirby-Bauer method. A 
filter paper disc impregnated with chemical is placed on agar and the chemical diffuse into the agar 
around the disc. For this method to give reliable results, the conditions and execution must be 
standardized including the medium, amount of microbes in dilution, concentration of chemical agent 
and incubation conditions. The antimicrobial drug diffuses into the agar, establishing a declining 
concentration gradient around the disc. Zones of no growth can be seen in the area where the 
concentration of the chemical is the same or higher than the microbes MIC. The result (distance from 
disc centre to the periphery of the zone of clearance) is measured in millimeters. A Norwegian national 
agreement is reached for stratification of these distances into a sensitive (S), intermediate (I) or 




E test is a method combining the principles of the disc diffusion method and the dilution method. An 
E-test is a plastic strip with specific concentrations of an antimicrobial agent on one side and a MIC 
scale printed on the other side. After spreading a standard amount of bacteria in dilution on the agar, 
the strip is placed with the MIC scale heading up. The antimicrobial agent will then diffuse into the 
agar, and establish a consistent and stable concentration gradient under the strip. After incubation, the 
antibiotic gradient gives rise to an elliptical-shaped inhibitory area around the strip.  The MIC value is 






The first aminoglycosides were natural products of microorganisms. The very first aminoglycoside; 
streptomycin, was isolated from the bacterium Streptomyces griseus in the 1940`s and used clinically 
against tuberculosis. Several different types of aminoglycosides have Streptomyces spp. as their 
source; neomycin, tobramycin, paromycin, kanamycin, amikacin, arbekacin and spectinomycin. 
Micromonospora spp. is the source of gentamicin and netilmicin. Gentamicin is a mixture of several 
antibiotic components produced by fermentation of Micromonospora purpurea and other related soil 
microorganisms. Gentamicin and the other newer agents of the aminoglycoside family are so called 
semi synthetic agents. This implies that their natural basis has been synthetically modified to generate 




Aminoglycosides have a backbone structure consisting of an aminocyclitol ring (a pharmacophoric 
1,3-diaminoinositol moiety) either streptamine, 2-Deoxystreptamin or streptidine. The diaminoinositol 
unit is connected through glycosidic linkages to various amino sugars. The chemistry, spectrum, 
potency, toxicity, and pharmacokinetics of these agents are functions of the identity of the 
diaminoinositol unit and the arrangement and identity of the attachments. (10) 
 
 
Figure 1.3: (Figure adopted from(12)) 
 
  
Aminoglycosides are potent bactericidal antibiotics, mostly used against gram negative bacteria. They 
penetrate bacteria by binding to positively charged moieties of the cell membrane; this is believed to 
result in the displacement of Mg2+ and Ca2+ ions that link adjacent lipopolysaccharide molecules. The 
process damages the membrane and enhances its permeability(7).  Inside the cells they inhibit bacterial 
protein synthesis by binding to the ribosome. The precise mechanism of their antimicrobial activity is 
still a subject of study but all aminoglycosides bind to the 16-S-ribosomal DNA portion of the 30S 
ribosomal sub particle impairing the proofreading function of the ribosome. This leads to 
mistranslation of RNA templates and the consequent selection of wrong amino acids and formation of 
so-called nonsense proteins. The most relevant of these unnatural protein syntheses is the effect on 
bacterial membrane and its function. The defective membrane allows for large additional quantities of 
aminoglycosides to enter the cell. With increased concentration within the cell, protein biosynthesis 
ceases all together. The combined effects cause bactericidal death(10). 
The bactericidal effect of aminoglycosides is dependent on the drug concentration. The toxicity 
potential increases with increased concentration of the antibiotic. They exhibit post-antibiotic effect, 
which means that the bacterial death continues despite nil or very low drug levels. The concentration-
dependent effect and post-antibiotic effect in addition to risk of nephrotoxicity and ototoxicity are the 
major reasons for once-daily dosing(7). Because of the toxicity issues of aminoglycosides, there has 
been a trend of using β-lactams and other less toxic agents against bacterial infections over the last 
years. Nevertheless aminoglycosides remain important drugs against microbes and especially against 
multiresistant strains that are still vulnerable to these agents.  
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 Aminoglycosides are given parenterally because they are not absorbed in significant amounts from 
the gastrointestinal tract. There are several types of aminoglycosides with diverse antimicrobial spectra 
and therefore the choice of aminoglycoside for therapeutic purpose depends on the bacterial pathogen, 
for example gentamicin or netilmicin for gram negative intestinal bacteria (Enterobacteriaceae), 
tobramycin for Pseudomonas spp while streptomycin is usually reserved for Mycobacterium 
tuberculosis.  Aminoglycosides are often combined with other antimicrobial agents when used. 
Aminoglycosides produce synergistic bactericidal activity when given together with other agents 
inhibiting cell wall biosynthesis(7). Gentamicin and β-lactam antibiotic is one combination used, but 
there is an interesting incompatibility problem between the two. Certain β-lactam antibiotics N-
acetylate gentamicin on the C-1 position, inactivating both antibiotics(10). This makes it important not 
to mix the two components in the same solution and administer the two into different tissues 




1.3.1 Resistance against Aminoglycosides 
 
Many bacteria have inherent resistance to antibiotics; such resistance existed long before antibiotics 
were introduced as pharmaceuticals. Since microorganisms produce antibiotics themselves, they must 
have mechanisms protecting against these. Some bacteria are therefore inherent resistant against 
certain antimicrobial agents. In addition to inherent resistant strains, bacteria have the ability to 
acquire resistance, either by mutation of their own genes or by the acquisition of extrinsic genes on 
mobile genetic elements.  
Resistance can be defined as the ability of a microorganism to withstand the effects of a drug that are 
lethal to most members of its species. It can be caused by genetic changes in microbes that reduce or 
eliminate the effectiveness of drugs. Bacteria develop a variety of mechanisms to evade the lethal 
effect of antibiotics. With increasing exposure to antibiotics, new resistance mechanisms are 
developed or acquired by the organisms for their survival. Resistance against gentamicin in E.coli has 
increased in Norway over the last years according to surveillance data (see section 1.1). 
   
Resistance against aminoglycosides is claimed to be caused by one or more of the following 
mechanisms.(13) 
 
1) Aminoglycoside modifying enzymes (AME) that render the aminoglycosides incapable of 
binding to its ribosomal target. 
2) Decreased cell membrane permeability limiting aminoglycoside uptake into the cell 
3) Structural alteration in the ribosomal target hindering the attachment of the drug to its cite of 
action 




AME`s are the most important mechanism of resistance to aminoglycoside antibiotics (7, 12). The 
enzymes inactivate aminoglycosides by transferring a functional group to the aminoglycoside 
structure. This makes the aminoglycoside unable to interact with the ribosome effectively. There are 3 
types of enzymes that transfer different functional groups to the aminoglycoside structure: 
1) Aminoglycoside nucleotidyltransferases (ANT`s) transfer a nucleotide triphosphate moiety to 
a hydroxyl group 
2) Aminoglycoside acetyltransferases (AAC`s) transfer the acetylgroup from acetyl-CoA to an 
amino group 
3) Aminoglycoside phosphotransferases (APH`s) transfer the phosphoryl group from ATP to a 
hydroxyl group 
Each of the 3 families of enzymes is divided into classes according to the modification site on the 
aminoglycoside structure, indicated in parentheses. They are further divided according to their 
phenotypes (resistance profiles), indicated by roman numbers. Finally enzymes of the same type and 
phenotype but encoded by different genes are designated by a trailing lowercase letter (example 
AAC(6`)-Ib) (7).  More than 85 aminoglycoside modifying enzymes have been identified(14). 
Illustrating an example of the nomenclature; each class (parentheses) within a group have different 
phenotypes (roman numbers). So AAC(6`)-I and AAC(6`)-II have different resistance phenotypes. 
While the lower case letter illustrates different genes, so AAC(6`)-Ib and AAC(6`)-Ia have identical 
phenotype but are encoded by different genes. When writing the name of the genes for the enzymes, 
the term is written with lowercase letters in italics (aac(6`)-Ib). 
 
Figure 1.4: Aminoglycoside acetyltransferase showing their modification sites and respective phenotypes 




In this study we have included four classes of AAC`s; AAC(1), AAC(3), AAC(2`) and AAC(6`). We 
chose to investigate the presence of aac(6`)-Ib and aac(3)-IIc. 
 
Figure 1.5: Antibiotic resistance (phenotype) for each of the Aminoglycoside acetyltransferases. (Figure 
adopted from (7)) 
Substrate profiles of aminoglycoside acetyltransferases 
Enzymes: Substrate(s): 
AAC(6')  
    I (at least 24 enzymes) Tobramycin, amikacin, netilmicin, dibekacin, sisomicin, 
kanamycin, isepamicin 
    II Tobramycin, gentamicin, netilmicin, dibekacin, sisomicin, 
kanamycin 
AAC(3)  
    Ia, Ib Gentamicin, sisomicin, fortimicin 
    IIa, IIb, Iic Tobramycin, gentamicin, netilmicin, dibekacin, sisomicin 
    IIIa, IIIb, IIIc Tobramycin, gentamicin, dibekacin, sisomicin, kanamycin, 
neomycin, paromomycin, lividomycin 
    IV Tobramycin, gentamicin, netilmicin, dibekacin, sisomicin, 
apramycin 
    VII Gentamicin 
 
AAC(1) Paromomycin, lividomycin, ribostamycin, apramycin 
 




Of all the known AAC(6`)s, AAC(6`)-Ib is the most prevalent among the gram-negative 
microorganisms. The gene aac(6`)-Ib has been detected on either transposoms or integrons. It is 
reasonable to assume that the location of aac(6`)-Ib on mobile genetic elements has facilitated its rapid 
dissemination in the presence of selective antibiotic pressure among a wide range of 
microorganisms(7).   
AAC(3)s are widely distributed among different bacterial genera. They constitute the second largest 
group of aminoglycoside acetyltransferases, and are the second most common mechanism of 
aminoglycoside aacetyltransferase-mediated resistance in clinical isolates after AAC(6`)-I enzymes. 
aac(3)-II is widely distributed among gram negative bacteria(7).  
Even though there are more than 85 aminoglycoside modifying enzymes, only a limited number of 
them have been selected to cause the majority of aminoglycoside resistance; ANT(2``)-I, AAC(6`)-I 
and AAC(3)-I + II + III + IV + VI.(14). Our chosen enzymes AAC(6`)-I and AAC(3)-II are among the 






Aminoglycoside resistance mechanisms have become complex over time. Combinations of different 
mechanisms occur frequently in the same isolate, broadening the spectrum of aminoglycoside 





1.3.2 Co-resistance with Fluoro-quinolones 
 
Fluoro-quinolones and aminoglycosides are two different classes of antibiotics. The first generation of 
quinolones was introduced in the 1960`s, while the second generation, the fluoro-quinolones, were 
introduced to the marked in the 1980`s. Fluoro-quinolones are synthetic bactericidal agents. They 
inhibit DNA gyrase and topoisomerase IV. These key bacterial enzymes dictate the conformation of 
DNA. Inhibition of these enzymes makes the cell’s DNA unstable and leads to cell death.  
Bacteria are known to host enzymes providing resistance to antibiotics of natural origin. These 
enzymes have co-evolved with the antibiotics they inactivate and were thought to be specific for a 
single class of drugs or even selected members of a class (16). Fluoro-quinolones are as previously 
mentioned synthetic agents and thought to be spared for development of such a resistance mechanism 
(16). Independent mutations seemed to be the only threat. Since two or more resistance mutations are 
needed to reduce susceptibility to fluoro-quinolones and independent mutations take place once per 
107 cell division or less, the threat seemed negligible(17). Despite the presumption that fluoro-
quinolones seemed to be unlikely to develop resistance easily, resistance against fluoro-quinolones has 
become common and widespread(17).  
Quinolone resistance is mainly due to generation of efflux pumps, loss of porin channels or multiple 
chromosomal mutations in genes encoding quinolone target enzymes. The chromosomal genes 
encoding quinolone targets are; gyrA and gyr B encoding DNA gyrase, parC and parE encoding 
topoisomerase IV. Target alteration most frequently occur due to mutations in the gyrA gene, 
particularly in a region of the gene called QRDR (“Quinolone resistance-determining region”)(18).  
Lately plasmid mediated quinolone resistance (PMQR) determinants have been reported (17-19).  The 
determinants include; Qnr-proteins which belongs to the pentapeptide repeat family that protects DNA 
gyrase and Topoisomerase IV from the action of quinolone agents including newer fluoro-
quinolones(18, 19), AAC(6`)-Ib-cr which is described in the following section and QepA, an fluoro-
quinolone specific efflux pump protein(19). PQMR confer low resistance on their own, but act 







 Enzyme conferring resistance to both aminoglycosides and quinolones: 
Recent publications report the identification of a variant of the aminoglycoside modifying enzyme 
AAC(6`)-Ib, as a common occurrence in clinical gram-negative bacteria isolates(17, 20, 21). This 
variant called AAC(6`)-Ib-cr (cr for ciprofloxacin variant) has the ability to inactivate selected fluoro-
quinolones in addition to its original activity on aminoglycosides. The gene aac(6`)-Ib-cr may have a 
role in the frequently observed but incompletely understood strong epidemiologic association between 
ciprofloxacin and aminoglycoside resistance (16). 
The gene for this enzyme is characterized by two single nucleotide polymorphisms (SNP`s) giving rise 
to two amino acid substitutions, Trp102Arg and Asp179Tyr; both substitutions have been reported to 
be necessary for the acetylation and inactivation of ciprofloxacin (20). In another mechanistic and 
structural analysis of the enzyme; Asp179Tyr mutation was shown to be the main contribution for the 




1.3.3 Co-resistance with extended spectrum beta-lactamases (ESBL) 
 
Beta-lactamases are enzymes cleaving the 4 atom ring (beta-lactam ring) and such deactivating the 
antimicrobial property of beta-lactam antibiotics. Their increasing prevalence in certain bacterial 
families like Enterobacteriaceae, and the spread to other bacteria led to the development of  
cephalosporins  in the early 1980`s (23). Not long after cephalosporins were introduced to clinical 
practice, genes encoding extended spectrum beta lactamses (ESBL) were discovered. The genes 
showed nucleotide mutations in their parent genes encoding beta-lactamases,  leading to extension of 
the substrate spectra of the enzymes to include even the 3rd and 4th generation cephalosporins (23). 
ESBLs are capable of conferring bacterial resistance to penicillin, first-, second-, and third-generation 
cephalosporins and aztreonam (but not cephamycins and carbapenems)(23). 
SHV-2 is a gene encoding an ESBL. It differs from the SHV-1 gene encoding a regular beta-lactamase 
by replacement of glycine by serine at the 238 position. This mutation accounts for the extended 
spectrum properties and bacteria with these genes were probably selected due to the pressure of the 
increased use of third-generation cephalosporins after their introduction to clinical practice. A large 
number of TEM (beta-lactamse gene) derivates has been described over the past years, the majority of 
them being ESBL. Also CTX-M (beta-lactamase gene) types beta-lactamases with extended spectra 
exist, and these are the most frequent ESBL worldwide(23). There are other genes, but these 3 classes 
are the most important genes encoding ESBL in Norway(24). 
Many genes for ESBLs are found on plasmids, often large plasmids with multiple resistance genes, 
and studies imply that their rapid spread is caused either independent through effects of the antibiotic 
pressure or by plasmid transfer from organism to organism (23). These plasmids coding for 
multiresistance, frequently carry genes for ESBL in addition to genes encoding resistance against 
aminoglycosides and trimethioprim/sulfamethoxazole(23). Quinolone resistance mechanisms are also 
associated with ESBL.(23)  
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1.3.4 Different enzymes located on the same transposable genetic element 
(plasmids/transposomes/integrons) 
 
A recent publication of complete nucleotide sequences of plasmids present in 2 variants of 
internationally prevalent E.Coli (O25:H4-ST131) shows that the plasmids encode several ESBL and 
AAC(6`)-Ib-cr(25). Other observational studies present reports where the majority of the isolates with 
aac(6`)-Ib-cr also show an ESBL phenotype(20).  
Other publications of complete nucleotide sequences of plasmids shows that plasmids encode ESBL 
and aac(3)-II (aacC2)(26, 27). 
A study from Norways report that prevalence of plasmid mediated quinolone resistance genes; qnr and 
aac(6`)-Ib-cr is higher among ESBL producing isolates (19).The association between the presence of 
aac(6`)-Ib-cr in isolates with qnr is observed in Korea (21). This association was not found in 
previous observational studies from the United States (20, 28).  
Qnr was first found on Plasmid pMG25 (29), and its gene sequence was later reported(30). This 
plasmid also encodes AmpC, ESBL and FOX-5. Many plasmids have been sequenced over the years 
and plasmids with with qnr genes are reported to also contain multiple resistance genes like aac genes, 
bla genes (AmpC), FOX-5, DHA-1, OXA-30 and SHV-7 (beta lactamses), cat gene 
(chloramohenicol), QepA (efflux pumps), sul1 (sulphonamide) and AmpR(transcriptional regulator, 
beta-lactamases)(18) 
The coexistence of multiple resistance determinants on a single transmissible plasmid indicate that any 
drug to which resistance occurs would preserve resistance to the other antibiotics on that plasmid.  
Co transmission of plasmids with plasmid mediated quinolone resistance (qnr), aminoglycoside 
modifying enzymes (aac(6`)-Ib) and different extended spectrum beta lactamases can accelerate the 
pace at which we drive dangerous multidrug resistance development(17).  
 
1.4 Patterns of antibiotic prescription in Norway 
 
Sale of pharmaceutical agents in Norway is monitored and trends can be statistically analyzed. 
Antibacterial agents are sold thorough pharmacies and a prescription from a physician, dentist or 
veterinarian is required. The Norwegian prescription data base (NorPD) contains data for all 
prescription drugs handed out through pharmacies from 2004. Data from NorPD can be used to 
monitor and trace changes in use of pharmaceuticals. Specific numbers on antibacterial use in 
hospitals can be retrieved from “The hospital pharmacies drug statistics database”. Epidemiological 
surveillance of the consumption of antibacterial agents before 2004 is based on wholesaler’s statistics. 
The wholesalers database cover the total sale of medicaments from drug wholesalers to pharmacies 
and hospitals in Norway collected since the beginning of the seventies.  
Usually drug consumption is measured in DDD (Defined Daily Dosage). The measurement unit DDD 
is defined as the assumed average maintenance dose per day for a drug used for its main indication in 
adults. It is important to be aware that in many cases the prescribed dose may deviate from the DDD. 
22 
 




1.5.1 Introduction; Genes and gene transcription:  
 
Genes are located on the bacterial genome in prokaryotic cells and are structurally composed of DNA 
(deoxyribonucleic acid), which is a polymer of 4 distinct nucleotides linked together. The sequence of 
these nucleotides is fairly specific for the genes and determines the structure of the encoded proteins. 
The nucleotides consist of a phosphate group, sugar (2`-Deoxyribose) and a nitrogenous base. The 
nitrogenous base differentiate the nucleotides and can be either Adenine (A), Cytosine (C), Guanine 
(G) or Thymine (T).  The nucleotides are linked together with phosphodiester bonds forming 
polymers. Two polymers are assembled in the structure of a double helix linked together by base 
pairing rules with hydrogen bonds and π-π interactions. 
Genes represent single units of information which is expressed to construct and maintain a living 
example of an organism. The resistance genes in focus are protein-coding genes whose biological 
information is required by the cell at a particular time. The genes are transcribed into RNA and further 
translated into proteins. Transcription is executed by DNA-dependent RNA Polymerases after strict 
base pairing rules. Translating RNA is more complicated, and uses the genetic code to specify which 
amino acids will be included in the specific sequence. The genetic code consists of triplets of 
nucleotides (Codons), defining which amino acid will be inserted. One amino acid may be coded by 1 
or up to 6 codons. The biological properties of the protein are determined by the order of the amino 
acids in addition to its folded structure and spatial arrangement of its chemical groups on the surface. 
The enzymes carrying out translation and transcription have characteristics making them able to carry 
out their jobs with great accuracy. Even so, errors do occur like single nucleotide polymorphisms 
(SNP). SNP is a position in the DNA where one nucleotide is different from what base-pairing rules 
demands. An SNP can be irrelevant, but sometimes the SNP in a gene alters the structure and the 
function of the protein that it encodes. In the case of AAC(6`)-Ib; two SNPs alter the amino acid 











1.5.2 Prokaryotic genome 
 
The physical organization of the prokaryotic genomes is different from the eukaryotic genomes. Most 
of what is known of the organization of DNA in prokaryotes is from studies of E.Coli. The genome of 
E.Coli is a single circular DNA molecule, supercoiled to a compact structure localized in the 
cytoplasm of the cell. This is called the bacterial chromosome, even though the structure has few 
similarities with eukaryotic chromosomes.  
Prokaryotes have plasmids which are small pieces of DNA, often but not always circular, that coexist 
with the chromosome in bacterial cells. Some plasmids are able to integrate within the chromosome, 
but others are thought to be permanently independent. Plasmids carry genes that are not usually 
present in the main chromosome and they are generally beneficial for the organism. Often these genes 
encode antibiotic resistance(31).Plasmids can also be conjugative, which means that they can move 
between bacterial species(32).   
Prokaryotes also have genetic elements like transposable elements. These are molecules of DNA that 
can move from one site on the chromosome to another.  Transposons are one example of a 
transposable element and they can confer drug resistance. The important feature of transposons is the 
presence of a gene encoding transposase, an enzyme necessary for transposition, and the presence of a 
short inverted terminal repeat (IS) at the end, which is involved in the transposition process. 
Transposons can also be conjugative (see below). Integrons are transposable elements that capture and 
express genes from other sources. These are unlike transposons highly selective in their insertion site. 
One important feature of integrons is the presence of a gene encoding the protein integrase, and the 
presence a specific DNA sequence allowing the intergrase to insert cassettes of genes along with a 
promotor. Integrons can become a part of chromosomes, transposones and plasmids(32). 
The content of the prokaryotic genome with its transposable elements and plasmids that allows for 




1.5.3 Transferability to other bacteria 
 
There are three mechanisms for genetic exchange; transduction, transformation and conjugation. 
Transduction is transfer of genes from cell to cell by a bacterial virus (bacteriophages). Transformation 
is a process where free DNA is incorporated into a recipient cell due to some prokaryotic cells being 
capable of taking up free DNA from the environment. This happens naturally only in a few bacterial 
species. 
The main mechanism of transfer of plasmids is conjugation. This is a replicative process, where both 
cells end up with copies of the plasmid. A region of genes called tra region is present if plasmids are 
transmissible. These genes encode proteins that function in transfer and replication, and other that 
function in mating pair formation(32). 
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Bacterial conjugation is genetic transfer which involves cell-to-cell contact. A copy of a plasmid is 
transferred to a new host and sometimes other genetic elements can tag along. The genes in the tra 
region of the conjugative plasmid are involved in the synthesis of sex pili on the surface structure. 
They allow pairing to take place between a donor cell and a recipient cell. DNA synthesis of 
complementary strand begins, and at the end of the process, both the donor and the recipient would 
possess completely formed plasmids(32).  
These 3 processes are mechanisms of horizontal gene transfer.  
Resistance plasmids infectious nature permits their rapid spread through cell populations. Resistance 
plasmids are now a major problem in clinical medicine (32). The same plasmids are sometimes found 




1.5.4 Techniques to study DNA 
 
 Techniques to study DNA was assembled in the 70`s and 80`s when different enzymes were purified 
and the reactions they catalyzed studied. Examples of enzymes are; DNA polymerases who synthesize 
DNA, DNA nucleases which can remove nucleotides from the end (exonucleases) or cut the sequence 
into shorter fragments (endonucleases), DNA ligases that join DNA fragments together again. The 
purified enzymes were adapted as tools for manipulating DNA molecules forming the basis of 
recombinant DNA technology. In recombinant DNA technology enzymes are used as tools cutting 
DNA molecules in to shorter fragments and joining them together. There can be combinations made 
that do not exist in nature. New or “recombinant” DNA molecules are constructed from pieces of 
naturally occurring chromosomes and plasmids.  
Recombinant DNA technology led to the development of gene cloning, in which short DNA fragments 
are inserted into a plasmid or a virus chromosome and then replicated in a bacterial or eukaryotic host. 
The next major breakthrough was Polymerase chain reaction (PCR), which gave the opportunity for 
repeated copying of a short segment of DNA. PCR techniques are now generally well established and 
easy accessible, and has become immensely important in many areas of research.  
 
 
1.5.5 Polymerase chain reaction (PCR) 
 
PCR is the repetitive copying of a targeted region of a DNA molecule. It has become increasingly 
important in biological research. Some of its areas of use are screening of human DNA for mutations 
associated with genetic diseases, obtaining sequences from trace amounts of DNA in forensic 
investigations or from archaeological sites, and it can be used to detect microbial pathogens in various 
infections. The technique has certain limitations, the main limitation being the need to know the 
genetic base sequence, or at least parts of the sequence, to be able to synthesize copies of it. 
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 The copying is carried out by a thermostable DNA polymerase that synthesizes DNA. The 
polymerase is dictated by the sequence being copied, via base-pairing rules. The polymerases also 
have proofreading ability, making them able to correct errors by removing a nucleotide that has been 
inserted incorrectly.  Polymerases always synthesize in 5`-3`-direction.  In order for the polymerase to 
work there must be a short double stranded region to provide a 3`-end onto which the enzyme will add 
new nucleotides. In PCR, primers are used for this purpose. Primers are short synthetic 
oloigonucleotides, usually about 20 nucleotides in length. They attach to the target DNA at either side 
of the segment that is to be copied. To design correct primers the sequence of the target gene segment 
must be known. 
Two types of platforms for PCR exist; Conventional PCR and Real-time PCR. The principles behind 
the amplification methods are the same, but the difference lies in the detection of the amplified 
product. In conventional PCR the results are assessed on agarose gel, while real-time PCR allows for 
detection while the reaction is ongoing.  Conventional PCR is therefore a more time consuming 
method due to laborious post PCR methods. Real-time PCR is chosen as method for this thesis.  





1.5.6 Detection of PCR product (specific probes/SYBRgreen) 
 
Different chemistries allow detection of PCR products via the generation of a fluorescent signal. 
TaqMan probes, Molecular Beacons and Scorpions depend on Förster Resonance Energy Transfer 
(FRET) to generate the fluorescence signal via the coupling of a fluorogenic dye molecule and a 
quencher moiety to the same or different oligonucleotide substrates. SYBR Green is a fluorogenic dye 
that exhibits little fluorescence when in solution, but emits a strong fluorescent signal upon binding to 
double-stranded DNA.  
A Taqman probe has a reporter dye on one end and a quencher dye on the other end of the sequence. It 
is designed to have an annealing temperature 8-10°C higher than that of the primers; so it anneals to 
the sequence before the primers do. This ensures detection of a specific variant since Taq polymerase 
has a 5`-exonuclease activity (proofreading ability) as well as polymerase activity Due to this 5`-
exonuclease activity Taq polymerase hydrolyzes the probe on encounter, releasing the reporter dye 
from the quencher. Once the probe is displaced, the polymerase continues amplification. The cleaved 
reporter gives rise to an increased fluorescent emission which is detected by the instrument. The signal 











SYBRgreen is used in an alternative detection. It binds to the minor grooves of any double stranded 
DNA and when bound it emits a fluorescent signal. The intensity of the fluorescent emission is 
proportional to the amount of double stranded DNA present. Thus, amplification could be monitored 


















1.5.7  Restriction enzymes 
 
Restriction enzymes are as mentioned in section 1.5.2 used in recombinant DNA technology. They can 
also be used to study single nucleotide polymorfs (SNP`s) in DNA.  
A restriction endonuclease binds to a specific sequence in the DNA molecule and makes a double 
stranded cut. Because of the specificity, the positions of the cut can be predicted and specific 
fragments will occur. After treatment with restriction endonucleases, the resulting DNA fragments can 
be examined by agarose gel electrophoresis to determine their size. Agarose gel electrophoresis is a 
method to separate DNA molecules of different length. Electrophoresis is the movement of charged 
molecules in an electric field. DNA molecules are negatively charged molecules and will migrate to 
the positively charged electrode. The pores of the gel impede larger molecules from travelling towards 
the electrode. Molecules of different length are therefore separated and shown as bands in the gel. The 
fragment produced by the use of endonucleases should always be the same due to its specificity of the 
cut, but this is not true if an SNP is present. If the restriction sites are polymorphic, then only the DNA 
sequence with the “correct” allele will be recognized and cut while the sequence with mutation will 




1.5.8 Sequencing the amplicons  
 
To gain information on the sequence of the nucleotides encoding a gene, several procedures are 
available. The traditional method is the chain termination method. After the discovery of thermostable 
DNA polymerases, which also led to PCR, a new methodology called thermal cycle sequencing was 
developed. The difference between the traditional method and the thermal cycle sequencing method is 
the material needed. The thermal cycle method requires very little template DNA and uses double 
stranded DNA as template, while the traditional method requires single-standed DNA and the 
necessity of cloning to get enough material. 
Thermal cycle sequencing is carried out in a similar way to PCR, but just one primer to anneal to the 
same position in each molecule is needed. The reaction mixture contains DNA polymerase, 
deoxyribonuclease triphosphates (dNTP`s, dATP`s,dCTP`s,dGTP`s and dTTP,s) and a small amount 
of dideoxynucleotide triphosphates (ddNTP`s, ddATP`s,ddCTP`s,ddGTP`s and ddTTP`s). Each of 
these 4 last dideoxynucleotides is labeled with a different fluorescent marker. The polymerase enzyme 
does not discriminate between deoxynucleotides and dideoxynucleotides. Every time a 
dideoxynucleotides is incorporated into the newly synthesized sequence the elongation is blocked. 
Because of the different amounts added to the solution, many sets of molecules of different lengths are 
synthesized, each with an ending dideoxynucleotide at the terminal end whose identity indicates the 
nucleotides A, C, G or T. The DNA mixture is loaded into wells of polyacrylamide slab gel, or into a 
tube of capillary gel system, and electrophoresis carried out separates the molecules according to their 
length. After separation, the molecules are run past a fluorescence detector capable of discriminating 
the labels attached to the dideoxynucleotides. The detector determines which nucleotide each molecule 
ends with, and the results can be analyzed.  
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1.5.9 Knockout/contemplation studies 
 
Complementation studies are experiments that can detect whether two mutations are in different 
regions of the same gene. This is a test for allellism and is also called cis-trans test. It is used to 
determine whether two mutant sites are in the same functional unit of the gene. The mutations must be 
recessive for this test to work. Basically if a wild-type phenotype is observed after mating two mutant 
strains, the two mutants are alleles of different genes. Each mutant has a functional version of the other 
gene. But if wild type function is not seen, the mutations are combined trans with one another and it is 
concluded that these are alleles of the same gene which means that neither allele produces a product 
that can restore wild-type function.  
 
Figure 1.9: (Figure adopted from (36)): 
 
Two different mutations on opposite chromosomes will not complement each other, while two mutations on the 












2 Aim of the study 
 
 
In our material of aminoglycoside resistant clinical isolates of Enterobacteriaceae collected in western 
Norway, the following objectives were addressed: 
1. Determine the susceptibility pattern to 6 different aminoglycosides; gentamicin, kanamycin, 
amikacin, streptomycin, netilmicin and tobramycin. 
2. Screening for the genes aac(6`)-Ib , aac(6`)-Ib-cr and aac(3)-II encoding aminoglycoside 
modifying enzymes, reported to be common in Enterobacteriaceae 
3. Relating the results of the susceptibility patterns for aminoglycosides and the presence of the 
selected genes 
4. Relating the presence of resistance phenotype for AAC(6`)-Ib-cr to ciprofloxacin resistance 





1. Possible association between increased use of ciprofloxacin and selection of combined 
aminoglycoside and ciprofloxacin resistance due to the selection of isolates possessing aac(6`)-Ib-
cr. 
 
2. Plasmid mediated resistance genes like ESBL and aac(6`)-Ib-cr being co-transferred 





















A total of 132 Enterobacteriaceae isolates where included in this study, from two localisations; Blood 
(n=50) and isolates from various localisations, but mainly form urine (n=82) with ESBL/AmpC or 
other mechanisms conferring resistance agaist 3rd generation cephalosporins.  
 
All isolates had shown reduced sensitivity or resistance to the tested aminoglycoside (gentamicin or 
netilmicin) on routine testing at the bacteriology department, Haukeland University Hospital. The 
blood culture isolates were from January 2000-June 2009 and the ESBL/AmpC/ other mechanisms 
conferring resistance agaist 3rd generation cephalosporins isolates were from 2006.  
(The ESBL/AmpC/ other mechanisms conferring resistance agaist 3rd generation cephalosporins 
isolates are for future reference shortened to ESBL isolates) 
 
 
Detailed description of routine examinations of the included isolates together with results from this 






The control strains used were given to us by K-Res (The Norwegian center of expertise for antibiotic 
susceptibility testing) . 









Table 3.1: Reference strains 
 Specimen number Strain Origin 
Quality control 
(E-test, MIC Test 
Strips) 
ATCC®25922 E.Coli ATCC 
Positive control 
(Aac(6`)-Ib-cr 
K-37-80 E.Coli K-res 
Positive control 
(Aac(6`)-Ib 








Table 3.2: Bacterial growth media used in this study: 
Medium Content 
Blood agar Distilled water (RO-water), Colombia Blood Agar Base, 
Sheep’s blood, Isovitalex without glucose.  
Lactose agar 
  
Distilled water (RO-water), Lab Lemco Powder, 
Bacteriological Peptone, Sodiumchloride (NaCl), Agar 
No.1, di-sodiumhydrophosphate dihydrate 
(Na2HPO4x2H2O), Lactose (C12H22O11xH2O), 
Sodiumthiosulphate Penthydrate (Na2S2O3xH2O), 0,2% 
Bromothymol blue (C27H28Br2O5S), 0,1% Chrystal violet 
(C25H30ClN3)  
Mueller Hinton Distilled water (RO-water), BBL Müeller Hinton Agar II, 
Sodiumchloride (NaCl) 
Greaves solution Distilled water (RO-water), L-Glutaminacid sodiumsalt, 





































E-tests and other types of strips 
Table 3.3: E-tests and MIC test strips used: 
Method Chemical Manufacturer 
   
E-test Gentamicin 
Etest strips with range  
 0,016-256 µl/mL 
AB Biodisc, Solna, Sweeden 
 Kanamycin 
Etest strips with range  
0,016-256 µl/mL 
AB Biodisc, Solna, Sweeden 
 Streptomycin 
Etest strips with range  
 0,064-1024 µl/mL 
AB Biodisc, Solna, Sweeden 
 Amikacin 
Etest strips with range  
 0,016-256 µl/mL 
AB Biodisc, Solna, Sweeden 
 Netilmycin 
Etest strips with range  
 0,016-256 µl/mL 
AB Biodisc, Solna, Sweeden 
 Tobramycin 
Etest strips with range  
0,016-256  µl/mL 
AB Biodisc, Solna, Sweeden 
 
MIC test strips 
 
Gentamicin 





MIC Test strips with range  
 0,016-256 µl/mL 
LIOFILCHEM, Italy 
 Streptomycin 





















Preparing the bacteria: 
 
The isolates were kept in the freezer at – 90 °C in Greaves solution. A scoop of bacteria were swabbed 
on blood agar and incubated overnight at 35°C. These cultured bacteria were used for further analyses. 
A Quality control strain was similarly incubated. 
  
E-test and MIC Test Strips: 
 
All blood culture isolates were tested with E-test and defined as sensitive, intermediate resistant or 
resistant using epidemiological cutoffs obtained from AFA/EUCAST. The procedure adhered to the 
guidelines issued in “E-TEST Technical Manual (ETM)” at AB Biodisc homepage(37): 5) 
Enterobacteriaceae (EAS 004), gram negative aerobes updated 2007-06.  
Procedure: 
1) The bacteria were suspended in 0,85 % sodiumchloride to 0,5 McFarland (1 McFarland for 
mucoid strains). 
2) Quality control strain identically suspended.  
3) These suspensions were swabbed on Mueller Hinton agar within 30 minutes after making.  
4) The Agar was left to dry for at least 15 minutes before E-tests were applied with a vacuum-
pen.    
5) Incubation over night at 35 °C for 16-20 hours. 
6) The results of each test were agreed by 2 observers. 
 
All Urine isolates where tested with MIC Test Strips and defined as sensitive, intermediate resistant or 
resistant using epidemiological cutoffs obtained from AFA/EUCAST. The procedure was based on the 
procedure recommended by Liofilchem in a leaflet sent with the product.  
1) Morphologically similar colonies were suspended 0,85 % Sodiumchloride 
2) A quality control strain was identically suspended  
3)  The turbidity was compared to the appropriate McFarland standard. (0,5 McFarland) 
4) The suspensions were swabbed on Mueller Hinton agar within 30 minutes after making.  
5) The Agar was left to dry for at least 15 minutes before E-tests were applied with tweezers.  
6) Incubation over night at 35 °C for 16-20 hours. 








3.2.2 Selected genes 
  
 
aac(6`)-Ib and aac(6`)-Ib-cr 
The sequence for the genes aac(6`)-Ib and aac(6`)-Ib-cr was searched for using NCBI`s Nucleotide 
database search.  The search was done within the strain E.Coli to reduce the number of hits. Basic 
Local Assignment Search Tool (BLAST; http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) was used to 
align two nucleotide sequences at the time. First the only focus was finding the two SNP responsible 
for the difference between the two genes causing amino acid change; Trp102Arg and Asp179Tyr. A 
total of 8 sequences for the gene aac(6`)-Ib and 6 sequences for the gene aac(6`)-Ib-cr was found (see 
APPENDIX 5). 
Due to several spotted differences between the base sequences, a map was created over all base 
variations to better find a suited area for primers and the probe (see APENDIX 6).  This was done 
using the FASTA sequence from Escherichia coli strain 2098EC (GenBank number: FJ619242), 
encoding AAC(6`)-Ib and search in the nucleotide selection among Enterobacteriaceae species to find 
highly similar matches. The variations spotted were manually outlined in the FASTA sequence, and 
the areas of variations were avoided when choosing appropriate primers and probes.  
aac(3)-II 
The inclusion criteria used in this study was isolates reported resistant against gentamicin or netilmicin 
from routine investigations. In E.coli, gentamicin resistance is reported to be most commonly 
mediated by AAC(3)s and ANT(2``)-I enzymes(14). AAC(3)s are frequently found in Gram negative 
bacteria (7).  This led us to screen for the presence of aac(3)-II as a possible cause for gentamicin 
resistance in the selected isolates. 
The gene aac(3)-II has several subtypes. The primers chosen from publication would detect subtypes 
aac(3)-IIa and aac(3)-IIc according to the software DNA star Laser gene Seqman. A comparison of a 
total of 47 published gene sequences was performed prior to choosing a suitable pair of primers.  
 
The theoretical specificities of all the chosen primers and probe sequences were tested with the Basic 










3.2.3 Extraction of DNA 
 
The procedure used was based on standard laboratory procedures for gram negative aerobes 
(Enterobacteriaceae) in use at Haukeland University Hospital, department of Microbiology. The 
process listed below lyses the cells and releases the DNA for PCR reactions. 
Procedure: 
1) 8-15 morphologically similar colonies where mixed in 0,5 ml sterile distilled water in an 
Eppendorf tube. Each sample was mixed on a Vortex mixer. 
2) The tubes were heated on hot stones. To release the DNA from the bacteria the heat was kept 
at 100 °C for 5-10 minutes. 
3) After cooling the suspension down to room temperature, the samples where centrifuged for 5 
min at 13 000 rpm. The supernatant containing the DNA were kept frozen until usage. 








 Initial screening for all aac(6`)-Ib: 
 
 
The primers and probe were designed using Applied Biosystem`s Primer Express 3.0 
 
Table 3.4: Oligonucleotide primers and probe used for PCR: 
Gene target: Primer / 
Probe: 















 MGB Probe 
(6-FAM) 
 










Table 3.5: Kits used in this study: 
Method Reagent  Manufacturer: 
RT-PCR  
(Screening for aac(6`)-Ib) 
TaqMan®Universal PCR Master Mix. 
 Contains:  
-AmpliTaq Gold DNA Polymerase 
-AmpErase UNG, 
-dNTPs with dUTP,  
-Passive Reference 
-Optimized buffer components 
 





Screening for aac(6`)-Ib was carried out by real-time PCR using specific primers and a probe designed 
for this study. PCR was done with a final volume of 20 µl; using 5 µl template, 10 µl 
TaqMan®Universal PCR Master Mix, 250nM probe and 900 nM of each primer. The instrument used 
was Applied biosystem 7500/7500 Fast real-time PCR system and standard cycling parameters was 
used; holding phase a; 50 °C for 2 min, holding phase b; 95 °C for 10 min to activate the enzymes, 




Amplification of longer segment to identify aac(6`)-Ib: 
 
The primers used were from the published study; Prevalence in the United States of aac(6`)-Ib-cr 
Encoding a Ciprofloxacin-Modifying Enzyme; Chi Hye Park, Ari Robicsek et.al.(28) with a 
modification in the forward primer. 
The probe was designed using Applied Biosystem`s Primer Express 3.0. 
Table 3.6: Oligonucleotide primers and probe used for PCR: 
Gene target: Primer / 
Probe: 






























Table 3.7: Kits used in this study: 
Method Reagent  Manufacturer: 
RT-PCR 
 (aac(6`)-Ib)  
 
TaqMan®Universal PCR Master Mix. 
 Contains:  
-AmpliTaq Gold DNA Polymerase 
-AmpErase UNG, 
-dNTPs with dUTP,  
-Passive Reference 
-Optimized buffer components 
 
Premix Ex Taq™ (Perfect Real Time) 
Contains: 
-TaKaRa Ex Taq ™ HS,  
-dNTP Mixture,  
-Mg2+. 
Comes with separate tubes with: 
ROX™ Reference Dye 
ROX™ Reference Dye II 
 








Takara BIO INC,  
AH Diagnostics, OSLO 
 
 
Detecting aac(6`)-Ib was carried out by real-time PCR using specific primers and a probe designed to 
detect only aac(6`)-Ib and not aac(6`)-Ib-cr. . The first instrument used was Applied biosystem 
7500/7500 Fast real-time PCR system and was done with a final volume of 20 µl; using 5 µl template, 
10 µl TaqMan®Universal PCR Master Mix, 250nM probe and 900 nM of each primer.  Special 
cycling parameters was used; first a holding phase ; 95 °C for 10 min to activate the enzyme 
AmpliTaq Gold DNA Polymerase, then cycling parameters; 94 °C for 45 sec, 55 °C for 45 sec and 72 
°C for 45 sec for 34 cycles as used in the article from where the primers sequences were found. Later 
standard cycling parameters was tried; holding phase a; 50 °C for 2 min, holding phase b; 95 °C for 10 
min to activate the enzymes, then cycling parameters; 95 °C for 15 sec and 60 °C for 1 min for 40 
cycles. 
The second instrument used was a Smartcycler® with a final volume of 25 µl; using 2 µl template, 
12,5 µl TaqMan®Universal PCR Master Mix or Premix Ex Taq™ (Perfect Real Time), 220 nM probe 
and 450 nM of each primer. The cycling parameters used was; holding phase ; 94 °C for 15 sec, then 
cycling parameters; 94 °C for 45 sec, 55 °C for 45 sec and 72 °C for 45 sec for 34 cycles as used in the 















 Screening for all aac(3)-II: 
 
The primers used were from the published study; Occurrence of antibiotic-resistant enterobacteria in 
agriculture foodstuff, Sybille Boehme, Guido Werner et.al(38) 
The primers suitability to detect subtypes of aac(3)-II was assessed using BLAST and the software  
DNA Star Lasergene Seqman. They will detect the following subtypes:  aac(3)-IIa, aac(3)-IIc  
 
 
Table 3.8: Oligonucleotide primers and probe used for PCR: 
Gene target: Primer / 
Probe: 















Table 3.9: Kits used in this study: 
Method Reagent  Manufacturer: 
RT-PCR 
 (aac(3)-II) 
SYBR® Premix Ex Taq™  
(Perfect Real Time) 
Takara BIO INC,  
AH Diagnostics, OSLO 
 
Detection of aac(3)-II was carried out using Smartcycler® with SYBRgreen reagents with a final 
volume of 25 µl using; 2 µl  template, 12,5 µl SYBR® Premix Ex Taq™ (Perfect Real Time) and 
200nM of each primer. The cycling parameters used was; holding phase ; 95 °C for 120 sec, then 




3.2.4 Sequencing of all aac(6`)-Ib 
 
 
Duplicate amplification of all positive isolates from “screening for aac(6`)-Ib” was performed. The 
PCR product from “amplification of longer segment to identify aac(6`)-Ib-cr “could not be directly 
sequenced due to the presence of a probe in the product. Probes interfere with sequencing and the 
cleaning kit used; ExoSAP-IT is not recommended for cleaning probes from a PCR product. ExoSAP-
IT will however clean primers and unconsumed dNTP`s from a PCR product.  
The primers used for the duplicate amplification were the same as used in “amplification of longer 




Table 3.10: Kits used in this study: 
Method Reagent  Manufacturer: 
RT-PCR 
(aac(3`)-II) 
SYBR® Premix Ex Taq™ (Perfect Real 
Time) 
 
Takara BIO INC,  
AH Diagnostics, OSLO 
Screening preparation 
 
ExoSAP-IT for PCR Product Clean-Up 
Contains:  
-Exonuclease I 
-Shrimp Alkaline Phosphatase 
-Specially formulated buffer 
 
ABI PRISM BigDye Terminator Cycle 
Sequencing Ready Reaction Kit 1.1 
Contains: 
• Ready Reaction Mix 
• pGEM®-3Zf(+) double-stranded 
DNA Control Template 
• –21 M13 Control Primer (forward) 
• BigDye Terminator v1.1/3.1 










Applied Biosystems, Bleiswijk, 
Netherlands 
 
Duplicate amplification of aac(6`)-Ib was carried out by real-time PCR using specific primers with 
detection by SYBRgreen. The instrument used was Smartcycler® and the reaction was done with a 
final volume of 20 µl; using 2 µl template, 12,5µl SYBR® Premix Ex Taq™ (Perfect Real Time) and 
200nM of each primers.  
 
Product clean up was perfomed in a DNA Engine Dyad® Peltier Thermal cycler by incubating a mix 
of template and ExoSAP-IT for 15 min. at 37°, thereafter deactivate the enzymes by incubating the 
mix at 80°C to for 15 min. Cycle sequencing was performed by using the forward primer. 
 





Prevalence of Ciprofloxacin resistance in different isolates were compared with Fisher Exact test (Five 












See APPENDIX 1-4 for complete results listed in tables. The tables contain:  
• Previously obtained data from routine practice.  
• Resistance profiles based on MIC values. 
• Data collected from preformed Polymerase chain reactions. 
 
 
4.1 Susceptibility tests: 
 
Figure 4.1: Proportion of isolates Resistant, Intermediate resistant or Susceptible to each Aminoglycoside 
tested. See Methods for details regarding categorization. (GM = Gentamicin, KM = Kanamycin, SM = Streptomyin,  







Presence of combination of antibiotic resistance previously reported to be associated with 
AAC(6`)-Ib and AAC(6`)-Ib-cr phenotypes: 
A total of 9 isolates were intermediate resistant (I) to amikacin in addition to resistance or intermediate 
resistance against kanamycin, netilicin and tobramycin consistent with the AAC(6`)-Ib profile. It’s 
noteworthy that none of the isolates were resistant (R) to amikacin.  
5 of these 9 isolates had previously been tested (Routine laboratory testing, Department of 
Microbiology, Haukeland University Hospital) resistant for ciprofloxacin and nalidixic acid, while 4 





~61 % of the ESBL isolates (50 of 82) were resistant (R) or intermediate resistant (I) against 
kanamycin, netilmicin and tobramycin. Of these; 8% (4 isolates) were additionally intermidate 
resistant to amikacin.   
Only 3 isolates were exclusively R/I to kanamycin, amikacin, netilmicin and tobramycin matching the 
phenotypic profile for AAC(6`)-Ib. The rest were R/I also to one or both of the two remaining 
aminoglycosides tested. 40 isolates (73%) were additionally gentamicin R/I. 30 isolates (55%) were 
additionally streptomycin R/I. 
 
 
Blood culture isolates: 
78 % of the blood culture isolates (39 of 50) were R/I against kanamycin, netilmicin and tobramycin. 
Of these 13% (5 isolates) were additionally amikacin intermediate resistant.   
None of the isolates were exclusively R/I to kanamycin, amikacin, netilmicin and tobramycin 
matching the phenotypic profile for AAC(6`)-Ib. All showed resistance to one or both of the two 
remaining aminoglycosides tested. All 39 isolates (100%) were additionally gentamicin R/I. 25 (64%) 









Ciprofloxacin susceptibility results from routine work at Haukeland University hospital: 
relevant results 
Co-resistance of fluoroquinolone and the three aminoglycosides kanamyin, netilmycin and 
tobramycin, but without reduced susceptibility to amikacin was frequently observed in the isolates of 
the present study.  Of the 46 ESBL isolates that showed this aminoglycoside resistance phenotype, 41 
isolates were resistant to ciprofloxacin. Of the 34 blood culture isolates, 29 isolates were resistant and 
1 isolate was intermediate resistant to ciprofloxacin (figure 4.3).  
 
Figure 4.2:  Column 1 shows the proportion of ciprofloxacin resistance among 9 isolates with resistance 
phenotypes consistent with aac(6`)-Ib. The two rightmost columns shows ciprofloxacin resistance co-existing 
with resistance or intermediate resistance to  kanamycin, netilmicin and tobramycin but not to amikacin  among 
















Presence of antibiotic resistance associated with AAC(3)-II phenotype: 
 
A total of 95 isolates were intermediate resistant (I) against gentamicin, netilicin and tobramycin 
consistent with the AAC(3)-II profile.  
 
ESBL isolates: 
64% of the ESBL isolates (52 of 82) were R/I against gentamicin, netilmicin and tobramycin, only 8 
isolates were exclusively resistant or intermediate resistant against these aminoglycosides matching 
the phenotypic profile for AAC(3)-II. The remaining isolates showed additional resistance (R) or 
intermediate resistance (I) to one or more of the 3 remaining aminoglycosides tested. 40 isolates (77%) 
were additionally kanamycin R/I. 30 isolates (58%) were additionally streptomycin R/I.  
 
Blood culture isolates: 
86 % of the blood culture isolates (43 of 50) were R/I against gentamicin, netilmicin and tobramycin, 
but only 4 isolates were exclusively resistant or intermediate resistant against these aminoglycosides 
matching the phenotypic profile for AAC(3)-II. The rest showed resistance (R) or intermediate 
resistance (I) to one or more of the 3 remaining aminoglycosides tested. 5 isolates are additionally 
amikacin I (12%), 39 isolates (91%) are additionally kanamycin R/I. 25 isolates (58%) were 




















4.2.1 Initial screening for aac(6`)-Ib gene. 
 
A total of 47 of 132 isolates were positive for the presence of the gene aac(6`)-Ib. 12 out of 50 isolates 
form blood culture and 35 out of 82 ESBL isolates. 
 
Figure 4.3.: Presence of aac(6`)-Ib in the initial screening. Blood culture (n = 50) Positive = Presence of gene, Negative 











Association with antibiotic resistance (AAC(6`) phenotype): 
A total of 89 of 132 isolates were resistant (R) or intermediate resistant (I) against kanamycin, 
netilmicin and tobramycin. Of these; only 9 isolates were amikacin intermediate resistant matching the 
resistance profile for AAC(6`)-Ib.   
Of these 9 isolates with matching resistance profile indicating the presence of AAC(6`)-Ib-cr; 4 were 
ESBL isolates and 5 were from blood culture isolates. All 4 (100%) of the ESBL isolates had the gene 
aac(6`)-Ib. Only 3 of the 5 isolates (60%) from blood culture had the gene aac(6`)-Ib 
 
 
Table 4.1:  The 9 isolates that are R/I to kanamycin, amikacin, netilmycin and tobramycin matching the resistant 
profile for aac(6`)-Ib. Only 7 have the gene encoding AAC(6`)-Ib or its variants. 
 
The isolates are divided after their phenotype (resistance profile). The phenotype is described with capital letters 
if resistant and small letters if intermediate resistant. 
 (G/g = Gentamicin, K/k= Kanamycin, S /s= Streptomyin, A/a = Amikacin, N/n = Netilmycin, T/t = Tobramycin.) 
 
Phenotype aac(6`)-Ib or -cr variant no gene Phenotype aac(6`)-Ib or -cr variant no gene
 K a n T 3 0 G K S a N T 1 0






Summary- initial screening test: 
70 % (30 out of 50) of the isolates from the ESBL isolates with resistance or intermediate resistance to 
kanamycin, netilmicin and tobramycin had the gene aac(6`)-Ib. (Including the 4 isolates intermediate 
resistant to amikacin and the 26 that were sensitive to amikacin.)  
31% (12 out of 39) of the isolates from the blood culture isolates with resistance or intermediate 
resistance to kanamycin, netilmicin and tobramycin had the gene aac(6`)-Ib. (These include the 5 
isolates intermediate to resistant to amikacin and the 7 that were sensitive to amikacin.) 
 
The majority (~64%, 30 out of 47 isolates) of the isolates with aac(6`)-Ib were resistant to at least 3 of 
the relevant aminoglycosides; kanamycin, netilmicin and tobramycin. The rest of the isolates with the 
gene aac(6`)-Ib were only intermediate resistant to one or more of the aminoglycosides in focus.  
92 % (32 of 35) ESBL isolates positive for aac(6`)-Ib were kanamycin resistant. All of the isolates 




4.2.2 Subsequent amplification of longer segment to find aac(6`)-Ib. 
 
As detailed in methods, the probe used in the subsequent procedure should detect only aac(6`)-Ib and 
not its variants with influence on the ciprofloxacin susceptibility. The presumption was that the 
procedure should exclude isolates with aac(6`)-Ib-cr variants from amplification.   
Results from real-time PCR using Applied Biosystem ingredients resulted in weak signals even for the 
positive control, and we could not ascertain whether the tested isolates had aac(6`)-Ib or not. Different 
approaches were made to improve the signal on the same machine; changing temperature settings, 
time intervals, concentrations of the ingredients etc, but all our attempts failed. 
An alternative approach was tried, screening the material on a Smartcycler® machine with different 
reagents. However, no signal was obtained from the positive control for aac(6`)-Ib using the same 
reagents previously used on the Applied Biosystem machine. However, a positive signal was obtained 
when using Takara reagents. All isolates which were positive for aac(6`)-Ib with initial screening 
(n=47) gave positive signal with the probe for aac(6`)-Ib, even the positive control for the variant of 
aac(6`)-Ib-cr. This excluded the probe for further use, since it could not differentiate the gene from its 
variants. See discussion for possible explanations for these results. 
Due to the inconclusive results, the amplicons were sequence analysed out in order to identify aac(6`)-
Ib and its variants.  
   
 
 
4.2.3 Results of genetic sequence analysis. 
 
The majority of the isolates initially screened positive for aac(6`)-Ib  had the variant aac(6`)-Ib-cr (44 
of 47). The two single nucleotide polymorfs that differentiat aac(6`)-Ib and aac(6`)-Ib-cr was found in 
each isolate replacing two T bases with C and G respectively. 
 
Figure 4.5: A total of 44 isolates have the gene encoding aac(6`)-Ib-cr. All of the isolates with ESBL (100%) and 
9 isolates (75%) collected from blood culture. Only 3 blood culture isolates have the gene encoding aac(6`)-Ib. 
   
48 
 
Of the total of 132 isolates 44 have the gene aac(6`)-Ib-cr. 34 of these 43 isolates with aac(6`)-Ib-cr 
possess ESBL and 1 possess plasmid AmpC.   
 
 





Association between the presence of aac(6`)-Ib and its variant and the phenotypic resistance 
profile 
9 isolates had the phenotype for aac(6`)-Ib-cr being intermediate resistant (I) to amikacin in addition 
to resistant or intermediate resistant (R) to kanamycin, netilmicin, tobramycin and ciprofloxacin. Only 
7 of these were screening positive for the presence of the gene. The sequencing results state that all of 
these 7 isolates have the variant of the gene aac(6`)-Ib-cr. 
 
 
Table 4.2: The 7 screening positive isolates with matching resistance profile to AAC(6`)-Ib-cr have the gene 
encoding this enzyme.  
Phenotype aac(6`)-Ib-cr aac(6`)-Ib Phenotype aac(6`)-Ib-cr aac(6`)-Ib
 K a n T 3 0 G K S a N T 1 0








Table 4.3: Phenotypic resistance profiles for the sequenced isolates which are susceptible to amikacin. 
Phenotype aac(6`)-Ib-cr aac(6`)-Ib Phenotype aac(6`)-Ib-cr aac(6`)-Ib
G K S N T 10 G K S N T 3 3
G k S N T 1 G k S N T
G K S n T 3 G K S n T 
G K N T 9 G K N T 3
G K n t 1 G K n t 
G k n T 1 G k n T 
K S N T 1 K S N T
K N T 1 K N T
K S n T 2 K S n T




Association between sequence results and ciprofloxacin resistance 
 
34 out of 35 screening positive ESBL isolates with the variant aac(6`)-Ib-cr were resistant to 
ciprofloxacin and nalidixic acid. All 9 screening positive from blood culture having the gene for 
aac(6`)-Ib-cr are resistant to ciprofloxacin according to the susceptibility performed as part of routine 
work at department of Microbiology, Haukeland Hospital. 2 out of 3 blood culture isolates having the 
gene aac(6`)-Ib are ciprofloxacin resistant.  
The prevalence of ciprofloxacin resistance was significantly higher in isolates with aac(6`)-Ib-cr 
compared to isolates without this particular gene (98% vs 67%, P<0,001) 
Ciprofloxacin resistance was not significantly different between the isolates with the aac(6`)-Ib and 
variant gene.   
 
There was observed a high prevalence of ciprofloaxacin R/I among blood culture isolates without the 
gene encoding AAC(6`)-Ib-cr (n=30)( 77%). See figure below. 








A total of 95 of 132 isolates were positive for the presence of the gene for aac(3)-II.  40 out of 50 
blood culture isolates, and 55 out of 82 ESBL isolates. 
 













Resistance phenotype associated with the presence of AAC(3)-II 
  
52 isolates with the gene aac(3)-II from the ESBL isolates were resistant or intermediate resistant to 
gentamicin, netilmicin and tobramycin consistent with the phenotype for AAC(3)-II. The majority 
were additionally resistant to one or more of the other tested aminoglycosides. The remaining 3 
isolates does not fit the phenotypic profile for AAC(3)-II due to susceptibility to one or more of the 
aminoglycosides in focus.  
All of the 40 of the isolates with the gene aac(3)-II from blood culture were resistant or intermediate 
resistant to gentamicin, netilmicin and tobramycin. The majority were additionally resistant to one or 




4.4 Association between presence of the genes aac(6`)-Ib-cr and aac(3)-II 
 
There was a high association between aac(6)-Ib-cr and aac(3)-II as 34 of 44 isolates with aac(6`)-Ib-
cr  have both genes. All 34 with both genes present were gentamicin resistant, while none of the 
remaining 10 isolates with only aac(6`)-Ib-cr were resistant to gentamicin.  
 





The ESBL and blood culture isolates compared different with respect to prevalence of aac(6`)-Ib-cr 
and aac(3)-II genes (Fig 4.12, P<0.01). The combination of aac(6`)-Ib-cr and aac(3)-II  genes were 













Table 4.4: Data from NorPD (Gentamicin and Tobramycin) The number includes the use amongst people of all 
ages, both sexes in the entire country of Norway.  
J01G Aminoglycosides Turnover by dosage (DDD) 
2004    25 432 
2005    31 509 
2006    33 472 
2007    35 862 
2008    33 724 
2009    34 721 











Table 4.5: Data from NorPD. The number includes the use amongst people of all ages, both sexes in the entire 
country of Norway.  
J01MA02 Ciprofloxacin Turnover by dosage (DDD) 
2004    555 748 
2005    606 853 
2006    674 026 
2007    748 975 
2008    805 226 
2009    822 339 






Wholesalers statistics (40-42): 
Table 4.6: Total sale of aminoglycosides and quinolones in Norway both to community pharmacies and 
hospitals/nursing homes. 
ATC ATC level name (DDD 
value)
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
J01G Aminoglycosides 0,05 0,05 0,04 0,06 0,07 0,07 0,06 0,07 0,07 0,07 0,07 0,07
J01GB01 Tobramycin (0,24 g P/ 
0,3 g inhal.sol.)
0,03 0,03 0,02 0,03 0,04 0,04 0,03 0,03 0,03 0,03 0,03 0,03
J01GB03 Gentamicin (0,24 g) 0,006 0,006 0,006 0,008 0,017 0,03 0,03 0,03 0,04 0,04 0,04 0,04
J01GB07 Netilmicin (0,35 g) 0,02 0,02 0,02 0,02 0,01 0 0 0 0 0
J01M Quinolones 0,3 0,33 0,35 0,4 0,43 0,47 0,52 0,57 0,62 0,67 0,7 0,7
J01MA01 Ofloxacin (0,4 g) 0,06 0,06 0,05 0,05 0,05 0,05 0,05 0,05 0,04 0,04 0,04 0,03
J01MA02 Ciprofloxacin (1 g O/ 
0,5 g P)
0,23 0,26 0,29 0,34 0,38 0,42 0,47 0,52 0,57 0,62 0,66 0,67




The use of ciprofloxacin has increased considerably according to wholesalers statistics. The use of 
Tobramycin has not increased, but gentamicin consume has increased slightly.  
It is important to keep in mind that these figures should be regarded as maximum figures based on the 
assumption that all products sold are actually consumed. The actual drug consumption is probably 



















5.1.1 Observations around phenotypic characterization 
 
After phenotypic characterization by interpreting MIC values for the six aminoglycosides using 
epidemiological cutoffs, it became clear that we could not easily determine which aminoglycoside 
modifying enzyme (AME) was present from the MIC results alone. Most isolates showed resistance to 
a variety of aminoglycosides indicating the presence of several AME`s and/or possible other resistance 
mechanisms. The results from PCR verified this by the detection of both aac(3)-II and aac(6`)-
Ib/aac(6`)-Ib-cr in several isolates.  
One of the observations related to the MIC values was the low prevalence of amikacin resistance 
among our isolates. Due to structurally differences among aminoglycosides, inactivation of amikacin 
is reserved to only a few aminoglycoside modifying enzymes. 
 Another observation was that the gene aac(6`)-Ib or aac(6`)-Ib-cr was detected in several of the 
isolates and their presence was not associated with resistance against amikacin but only reduced 
susceptibility in 9 out of 47 isolates.  The reason for this deviation could be either the use of different 
breakpoints in the published literature, reduced expression of the protein encoded by aac(6`)-Ib 
/aac(6`)-Ib-cr or modified enzyme protein with alterations in its substrate specificity, in our isolates. 
Our findings challenge the published information about the substrate specificity, as regards amikacin, 
of this enzyme.  
 As ciprofloxacin resistance was observed in isolates without the variant aac(6`)-Ib-cr, additional 
mechanisms must exist for fluoro-quinolone in these isolates. gyrA is the most prevalent in E.coli and 
might be the cause for ciprofloxacin resistance among isolates where aac(6`)-Ib was not 
found(43).The focus of this study was not to determine the cause of ciprofloxacin resistance, but to 
observe if there was a strong association between presence of aac(6`)-Ib-cr and ciprofloxacin 
resistance. Several studies state that PQMR`s like aac(6`)-Ib-cr show a low resistance expression on 
their own, but act additively with other resistance mechanisms like with qnrA(28) and that the 
presence of aac(6`)-Ib-cr is frequently associated with increase in the frequency of chromosomal 
mutations(21). A more comprehensive gene screening would be needed to investigate whether 
aac(6`)-Ib-cr increase resistance in isolates with other resistance mechanisms like qnrA. In addition 
ciprofloxacin susceptibility data in this study is based on VITEK results, VITEK state the isolates as 
resistant with MIC value >4 towards ciprofloxacin. MIC tests with E-rest strips for ciprofloxacin 
susceptibility should have been carried out to see if there was a higher degree of resistance among 







The aminoglycoside resistance phenotypes most likely arise as a result of multiple resistance 
mechanisms. We recognize the limitations of the present study with respect to this. Resources has 
limited the number of aminoglycosides tested as well as the number of genes tested. In addition it is 
important to bear in mind that the presence of the gene sequence, does not necessarily mean that the 




5.1.2 Aac(6`)-Ib  
(Initial screening) 
 
Several primers from previous publications were assessed for the aac(6`)-Ib screening PCR .  Due to 
numerous polymorphisms discovered within the sequence, we chose to design primers with annealing 
sites without any single nucleotide polymorphisms, using Basic Local Assignment Tool (BLAST; 
http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). When designing the primers and probe; amplicon length, 
primer length, % GC, 3`end for the primers, 5`end for the probe and annealing temperature for the 
primers and probe were all compatible with the design guidelines given by Applied Biosystem. Of all 
considered primers and probe sets, the selected set was the best choice. 
The important factor is that the probe should bind to the sequence before the primers do. The probe 
should have an annealing temperature 10 °C or more, higher than the primers. In this case the 
temperature difference was 14 °C ensuring annealing of the probe to target well before the primers do. 
This amplification and detection proceeded as expected. 
 The results showing the majority of the isolates with aac(6)-Ib among the isolates with ESBL. This 
indicates a high prevalence of the variant aac(6)-Ib-cr since there are strong associations between 











5.1.3 aac(6`)-Ib  
(Subsequent amplification of longer segment to find aac(6`)-Ib). 
 
The probe to detect aac(6`)-Ib was designed to cover one of the areas where a single nucleotide 
polymorph differentiate aac(6`)-Ib from aac(6`)-Ib-cr. We chose the area with the single nucleotide 
polymorph causing the amino acid substitution Trp102Arg for the probe. The second area with the 
amino acid substitution Asp(179)Tyr was not suited as the probe site due to several nucleotide 
polymorphisms around this area.   
The reason for choosing a probe to detect aac(6`)-Ib and not aac(6`)-Ib-cr was the discovery of a third 
SNP after using Basic Local Assignment Tool (BLAST). Both the base A and C were present as 
SNP`s in sequences for aac(6`)-Ib-cr. The codons AGG and CGG code for the same amino acid 
substitution in the protein sequence (Trp102Arg). This was checked with a translation tool 
(http://www.expasy.ch/tools/dna.html). To avoid having to use two probes in case of clinical isolates 
having A or C instead of T, we decided to design one probe detecting aac(6`)-Ib where T is the only 
option. This way we could subtract the number of isolates with aac(6`)-Ib from the total number of 
positives in the initial screening process to get the number of isolates with aac(6`)-Ib-variants. 
Because of the limitations set by the location of the SNP the probe designed was not ideal. The probes 
length, % GC and its 5`end were considered in the designing, according to the guidelines from 
Applied Biosystems manual.  Meeting the design guidelines on the 5`end gave us trouble. The probe 
can not have a G residue on the 5 `end due to its ability to quench of the reporter fluorescence, even 
after cleavage. There were several G residues present near the 5`end in the sequence. These G`s could 
not be included in the probe sequence leaving the SNP location too far to the left from what the design 
guidelines recommend. (see figure 5.1). 
 
Figure 5.1: Illustrates the recommended SNP site is according to Applied Biosystems manual. It should be 
situated in the middle third position or further to the right. This site is found by dividing the probe in 3 parts, 
followed by counting to the third base in the middle sequence. As our sequence consists of 16 bases each part 
consists of ~5 bases leaving base number 8 from the left side as the ideal position for the SNP as marked in the 
picture. Any one of the following bases to the right of this base can be the position for the SNP, but not the 2 last 
bases on the right end. Our SNP is situated too far left of the recommended area, as illustrated by the yellow 








In addition to the failure of meeting the guidelines for the SNP position, the annealing temperatures 
were not ideal and the amplicon length exceeded the recommended number of bases by 334 bases. The 
recommendation is that a probe should have an annealing temperature between 68-70 °C, while 
primers should have annealing temperatures between 58-60 °C. Our probe has the annealing 
temperature; 68 °C, while the primers have the annealing temperatures 62,3 °C and 62 °C. This leaves 
a difference between the probe and the primers annealing temperatures of only 6 °C and the 
consequent risk of the probe not annealing before the primers do as it is recommended that the 
difference should be 10 °C or higher.    
There were numerous point mutations discovered after the 3`end of the probe. Ideally the amplicon 
length should lie between 50-150 bases. This could not be done because of the presence of the 
variations in the sequence of the gene, thereby making it impossible to design primers targeting a 
shorter region. 
Several published primers for the sequence were considered, and one primer set stood out as the most 
suited. These primers amplify a sequence of 484 bases and come from the published article; 
“Prevalence in the United States of aac(6`)-Iv-cr Encoding Ciprofloxacin-Modifying enzyme, C.Park, 
A.Robicsek et.al.(28). This targeted region includes both SNP`s necessary for ciprofloxacin resistance 
reported in variants, and therefore they could be identified by sequencing of the PCR product. 
Unfortunately their annealing temperature was not separated by 10 °C or more from the designed 
probe as mentioned above, and an SNP discovered in the forward primers annealing site, led to the 
change of that specific base to an ambiguous base, capable of annealing to more than one specific 
base. In this case the base is called R and is capable of annealing to both A and G(44). 
Using the designed probe with the modified primers failed to give results on the Applied Biosystems 
machine. The real-time PCR showed indication of a signal, but the signal was weak and the positive 
control for aac(6`)-Ib could not be differentiated from the positive control for aac(6`)-Ib-cr. Several 
measures were made to try to increase the signal strength. The temperature settings were increased 
2°C at the time, from the annealing temperature used in the article from where the primers where 
obtained (55°), to 60°C which is just above the annealing temperature according to the design program 
used. The time intervals were increased and different concentrations of both template and mix were 
tested without any improvement in signal strength. To rule out an instrument error being the cause, we 
tested the same ingredients on a smart cycler where we got no signal. 
One possible explanation as to why the signal was low was the presence of AmpErase® uracil-N-
glycosylase which is activated at temperatures as low as 50°C. Our amplification temperature was 
55°C, and the possibility that the enzyme was active still could not be ruled out. This enzyme prevents 
re-amplification of carryover products by removing any Uracil incorporated into single or double 
stranded DNA. It is not active at 60°C which is standard amplification temperature. The possibility 
that the probe could work in a different mix led us to try a mix from Takara®, this gave strong signals 
but even the positive control for aac(6`)-Ib-cr came out as positive, making it clear that the probe 
under the Takara conditions, could not differentiate the two gene variants that is differed by a single 
base pair mismatch. This could be due to the specificity of the probe being dependent on the use of the 
commended ingredients. Using Sigma-Aldrich primers, Applied Biosystem probe and Takara 





A well designed probe is capable of differentiating sequences where only one SNP differentiates 
between to variants. A probe must have certain properties which are described in the manual for the 
design program we used. The limitations set by the location of the SNP made it difficult to design a 
probe meeting all these demands of the design guidelines. This led to the design of a probe not ideal 
for the real-time PCR technique used. The designing of a probe specific for the SNP failed, as the 
probe could not differentiate the two variants. Restriction enzyme could have been used to 
differentiate the variants but we proceed with sequencing the amplicons. All screening positive 








The majority of the isolates had the gene aac(6`)-Ib-cr compared to aac(6`)-Ib, and they were mainly 
found among our ESBL strains (35 of 44). The gene for this variant is associated with plasmids which 
can explain the high prevalence due to spread between bacteria (18, 20, 25). The gene is reported on 
plasmids with genes encoding several ESBL(25), in addition to being frequently observed in isolates 
with ESBL(19, 21). The results verifies observations in these previous publications, that there is a 
strong association between aac(6)-Ib-cr and presence and ESBL, both plasmid mediated resistance 
mechanisms. The high prevalence of this gene among ESBL producing strains (43%) also supports it 
being an infectious plasmid mediated resistance mechanism.  
There was noted a high prevalence of ciprofloxacin resistance especially among isolates from blood 
culture without the gene aac(6`)-Ib-cr, even so there was a statistically significant higher prevalence of 
ciprofloxacin resistance among the isolates with the aac(6`)-Ib-cr.  
Assumptions can be made regarding chromosomal resistance mechanisms being present in these blood 
culture isolates due to lack of other plasmid mediated resistance mechanisms like ESBL. Further 
investigations regarding the presence chromosomal resistance genes like gyrA, parC, which are 
frequently found in Enterobacteriaceae, need to be done before opposing the reasons behind the 









There is a high prevalence of the gene aac(3)-II in the included isolates which could explain the high 
frequency of gentamicin resistance.  The susceptibility tests conferred a resistance phenotype among 
the isolates consistent with presence of AAC(3)-II according to reports on this subject (see section 
1.3). There are reports claiming this enzyme to be a common resistance mechanism in gram negative 
bacteria (7), but more comprehensive gene screening would be needed to investigate this in further 
detail. In addition the presence of the gene encoding this enzyme does not by itself prove a causative 
relationship to gentamicin resistance. 
 
Sequencing of the isolates are needed to further investigate which variants of the genes encoding 
AAC(3)-II is present.  
 
Among the 44 isolates having the gene encoding the enzyme AAC(6`)-Ib-cr, there was a high 
frequency of the aac(3`)-II gene. (34 out of 44 isolates with aac(6`)-Ib-cr also possessed aac(3)-II).All 
of these isolates were gentamicin resistant. The remaining 10 isolates with aac(6`)-Ib-cr lacked 
gentamicin resistance. This observation led to the assumption that aac(6`)-Ib-cr and aac(3)-II could be 
transferred coexistent by plasmids. 
AAC(3)-II also termed aacC2 may be located on with plasmids(26, 45). It is associated with 
gentamicin resistance. Gentamicin resistance could be a secondary effect due to selection of multi 
resistant plasmids caused by the increasing ciprofloxacin use. The resistance genes for ESBLs, 
aac(6`)-Ib-cr and aac(3)-II are all associated with plasmids in several independent studies, and we 
wanted to address the possible association between these genes . 
A high prevalence of both of aac(6`)-Ib-cr and aac(3)-II  genes in the ESBL isolates, compared to the 
blood culture isolates, would be expected if these antimicrobial resistance genes was transferred 
together on plasmids encoding multiresistance. Indeed this combination was present in 30% of the 
ESBL isolates compared to 18% of the blood cultures, but this difference did not reach statistical 
significance. Care should be taken interpreting this statistics since test power was low (β=0.29) and a 















The susceptibility pattern of the tested aminoglycosides indicated the presence of multiple 
aminoglycoside resistance mechanisms in the Enterobacteriaceae isolates from western Norway. 
Since genes for either other aminoglycoside modifying enzymes or other mechanisms may be present 
in each isolate, a more comprehensive gene screening is required to characterize this further. 
The susceptibility pattern of the tested aminoglycosides in the Enterobacteriaceae isolates from 
western Norway also showed a low prevalence of amikacin resistance. 
The observed low resistance against amikacin among isolates with genes encoding AAC(6`)-Ib`s 
challenge the  published information about the substrate specificity of this enzyme. Further, the low 
prevalence of resistance against amikacin provides us with an aminoglycoside which can be used 
against multiresistant Enterobacteriaceae. 
The screening for the genes aac(6`)-Ib/ aac(6`)-Ib-cr and aac(3)-II encoding aminoglycoside 
modifying enzymes in the isolates showed a high prevalence of the genes. aac(6`)-Ib-cr was more 
prevalent among ESBL isolates suggesting its location on plasmids along with bla genes conferring 
the ESBL phenotype.   
The high prevalence of aac(6`)-Ib-cr in our isolates probably results from selection of isolates with this 
enzyme conferring reduced susceptibility to ciprofloxacin. A possible explanation for such a selection 
would be the increased prescription and use of ciprofloxacin over the past years. This study can not 
provide conclusive answers explaining the increasing resistance for gentamicin in Norwegian isolates. 
However, with a possibility of selection of gentamicin resistant isolates, it is reasonable to advocate 
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Abbreviations used in the following appendices: 
ECOFF/R = Epidemiological cut off values / Resistance 
GM = Gentamicin (MIC values gained from E-tests and MIC test strips from this work) 
KM = Kanamycin (MIC values gained from E-tests and MIC test strips from this work) 
SM = Streptomycin (MIC values gained from E-tests and MIC test strips from this work) 
AK = Amikacin (MIC values gained from E-tests and MIC test strips from this work) 
NC = Netilmycin (MIC values gained from E-tests and MIC test strips from this work) 
TM = Tobramycin (MIC values gained from E-tests and MIC test strips from this work) 
NAL = nalidixic acid (Quinolone) (Resistant if >32, numbers gained from clinical routine data) 
CIP = Ciprofloxacin (Quinolone) (Resistant if >4, numbers gained from clinical routine data) 
GEN = Gentamicin (Aminoglycoside) (Resistant if >16, numbers gained from clinical routine data) 
TOB= Tobramycin (Aminoglycoside) (Resistant if >16, numbers gained from clinical routine data) 
Res.code: Phenotypic resistance described by using: 
 – when sensitive (S) 
 small letters when intermediate resistant (I) and  
big letters when resistant(R). 
Screening aac(6`)-Ib: positive = presence of aac(6`)-Ib , detected by using primers and a probe designed for 
this work. 
Sequencing: Show witch variant of the gene was present: aac(6`)-Ib or aac(6`)-Ib-cr  
aac(3)-II: positive = presence of  aac(3)-II, detected by using primers from publication. 









APPENDIX 1: ESBL 
ECOFF/R ≤2/≥8 ≤8/≥32 ≤16/≥64 ≤8/≥32 ≤2/≥8 ≤2/≥8




1126974-1 M1 > 32 > 4 2 > 16 ESBL Positive aac(6`)-Ib-cr
E.Coli K-anT
1137335-1 M2 > 32 > 4 2 >16 ESBL Positive aac(6`)-Ib-cr
E.Coli  --s--t
1066997-1 M1
> 32 > 4 4 2 ESBL
E.Coli
Hyperproduction gKS--t
1069854-1 M1 > 32 > 4 4 2 TEM1/TEM2
E.Coli  -KS---
1069854-1 M2 > 32 > 4 4 4 ?
E.Coli  ------
1124307-1 M1 > 32 1 4 2 ESBL
Mmorg  --S---
1129620-1 M1 > 32 > 4 4 2 AmpC
Pvulg  ------
1148554-1 M2 4 <0,25 4 2 none
Cfreu  ------
1162535-1 M1 4 <0,25 4 2 Plasmid AmpC
E.Coli g-s--t
1167885-1 M1 > 32 > 4 4 4 AmpC
Koxyt  ------
1193623-1 M1 4 <0,25 4 8 Hyperproduction
Prot  --s---
1006848-1 M1 <2 <0,25 <1 8 Hyperproduction
Cfreu  ----n-
1012517-1 M1 > 32 1 <1 4 AmpC
E.Coli  -KS-NT
1017826-1 M1 > 32 > 4 <1 >16 ESBL Positive aac(6`)-Ib-cr
E.Coli  -K--NT
1116888-1 M1 > 32 > 4 <1 >16 ESBL Positive aac(6`)-Ib-cr
E.Coli  -K-anT
1154788-1 M1 > 32 > 4 <1 >16 ESBL Positive aac(6`)-Ib-cr
E.Coli  -K--nT
1156773-1 M1 > 32 > 4 <1 >16 ESBL Positive aac(6`)-Ib-cr
E.Coli  -K--nT
1164398-1 M1 > 32 > 4 <1 >16 ESBL Positive aac(6`)-Ib-cr
E.Coli
(from Blood)  -K-anT
1194307-1 M1 > 32 > 4 <1 >16 ESBL Positive aac(6`)-Ib-cr
E.cloa GKS-NT
1012331-3 M1
8 0,5 >16 >16 ESBL Positive aac(6`)-Ib-cr Positive
KPNPN GKS-NT
1012331-3 M2
16 > 4 >16 >16 ESBL Positive
E.Coli
(secretion from wound) GKS-NT
1012331-3 M3 > 32 > 4 >16 >16 ESBL Positive aac(6`)-Ib-cr Positive
Prett GkS--T
1014464-1 > 32 > 4 >16 8 ESBL
E.Coli G-S-NT
1014457-1 M1 > 32 > 4 >16 8 ESBL Positive
E.Coli Gks-NT
1021613-1 M1 > 32 > 4 >16 8 ESBL Positive
E.Coli G-s---
1048046-1 M1 > 32 0,5 >16 <1 ESBL Positive
E.Coli
(from Blood) K-res G-s---
1041884-1 M1 > 32 > 4 >16 8 AmpC Positive
E.Coli
128 K-res GkS-NT
1042728-1 M1 > 32 > 4 >16 8 AmpC Positive
E.Coli GKS-nt
1052086-1 M1 > 32 > 4 >16 4 ESBL Positive
E.Coli GKS-NT
1054763-1 M1 > 32 > 4 >16 >16 ESBL Positive aac(6`)-Ib-cr Positive
Sstan
(Fæces) K-res G-S-n-
1055260-1 M1 4 <0,25 >16 4 Plasmid AmpC
E.Coli
(Drensvæske) G-s-nT
1059115-1 M2 > 32 1 >16 4 ESBL Positive
E.Coli G---NT
1059771-1 M1 > 32 > 4 >16 4 ESBL Positive
E.Coli Gk--NT
1062251-1 M1 > 32 > 4 >16 8 ESBL Positive
E.Coli GK--NT Positive aac(6`)-Ib-cr
1064602-1 M1 > 32 > 4 >16 ESBL
Citro gKs--T
1066265-1 M1 8 <0,25 >16 >16 AmpC
E.coli GK--NT
1070356-1 M1 > 32 > 4 >16 >16 ESBL Positive aac(6`)-Ib-cr Positive
E.Coli G---nt
1084014-1 M1 > 32 > 4 >16 <1 ESBL Positive
E.Coli GK--NT
1090743-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positive
E.Coli
K-res G---nt
1093843-1 M2 > 32 > 4 >16 8 TEM1/TEM2 Positive
E.Coli G---NT
1105024-1 M1 > 32 > 4 >16 8 AmpC Positive
E.Coli GK--NT
1105220-1 M1 > 32 > 4 >16 >16 Plasmid AmpC Positive aac(6`)-Ib-cr Positive
34 24 0,75 0,38
32
2 0,5 64 4 12
3 1
6 16
1 0,5 48 96 4 6
1
4 3 >256 >1024 0,5 0,25 4
3 >1024 3 1
1,5
6 1 2 8 2
7 1
0,75 0,75
5 2 >256 >1024 0,38 0,19
0,38
8 0,5 2 8 2 0,75 0,5
1 4 0,75 0,5
1
10 4 8 24 1,5
11 0,38
0,38 3
9 1 4 2 8 1
24
12 1,5 6 32 6 1,5 1,5
48 12 4 8
1,5
14 0,5 48 64 6
15 0,75
12 24
13 0,75 3 4 2 4
16
16 0,5 48 16 12 6 16
48 8 12 6
16
18 0,5 24 6 4
19 0,5
4 12
17 0,38 32 4 4 4
32
20 256 32 128 3 8 24
24 768 2 0,5
24
22 32 32 1024 4
24 24
8 32
21 48 32 128 4 12
6
25 64 8 >1024 1 12 12
48 1,5 6
16
27 12 3 24 1 1
28 32 8
2
26 96 24 32 2 32
29 64 16 2 8 8
31 64 48 64 3
2
4





30 48 >256 384 1,5
8
33 32 8 48 0,75 6
>16
34 24 3 8 1,5 32
35 128 12








38 32 48 16 8 24
37 6 48 32 2 1,5
24
40 48 4 3 0,5
6
41 48 48 6 8 12 32
42 48 8 2 1 6
8
44 24 32 4 3 8 32






APPENDIX 2: ESBL 
ECOFF/R ≤2/≥8 ≤8/≥32 ≤16/≥64 ≤8/≥32 ≤2/≥8 ≤2/≥8




1106482-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1107015-1 M1 > 32 > 4 >16 8 AmpC Positiv
KPNPN
1107136-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1106570-1 M2 > 32 > 4 >16 8 AmpC Positiv
E.Coli (Secretion from abdomon)
1118926-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
Cfreu
1120730-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1123006-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1123537-1 M1 > 32 1 >16 4 ESBL Positiv
E.Coli
1123537-1 M2 > 32 1 >16 8 ESBL Positiv
E.Coli
1129329-1 M1 > 32 > 4 >16 2 ESBL Positiv
KPNPN
1137803-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli K-res
1136540-1 M1 > 32 > 4 >16 8 Plasmid AmpC Positiv
E.Coli
1137606-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1138489-1 M1 > 32 >4 >16 8 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1139965-1 M1 > 32 >4 >16 4 ESBL Positiv
E.Coli
1143686-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1144282-1 M1 <2 <0,25 >16 4 ESBL Positiv
E.coli
1140723-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
KPNPN
1149305-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr
E.Coli
1150540-1 M1 > 32 > 4 >16 4 ESBL Positiv
E.Coli K-res
1152126-1 M1 > 32 > 4 >16 8 AmpC Positiv
E.Coli K-res
1151427-1 M1 > 32 > 4 >16 8 Plasmid AmpC Positiv
E.Coli
1150060-1 M1 > 32 > 4 >16 8 ESBL Positiv aac(6`)-Ib-cr Positiv
P.Mir Selective flush
1157115-1 M1 > 32 > 4 >16 8 ESBL Positiv
E.Coli
1159470-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1173485-1 M1 <2 <0,25 >16 8 Positiv
E.Coli
1174970-1 M1 > 32 0,5 >16 8 ESBL Positiv
E.Coli
1174600-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1178447-1 M1 > 32 1 >16 2 ESBL
E.Coli K-res
1177688-1 M1 > 32 > 4 >16 8 AmpC Positiv
E.Coli
1179813-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1181265-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
1186295-1 M1 > 32 0,5 >16 8 ESBL Positiv
E.Coli
1188193-1 M1 > 32 > 4 >16 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
Styph (Fæces)
1187496-1 M1 4 <0,25 >16 8 ESBL
E.Coli
1189057-1 M1 > 32 > 4 >16 8 ESBL Positiv
Mmorg
1021313-1 M2 > 32 >4 >16 8 ESBL Positiv aac(6`)-Ib-cr Positiv
E.Coli
10068181 M1 >32 >4 ESBL Positiv aac(6`)-Ib-cr
E.Coli (blood)
1089888-1 M1 >32 >4 s ESBL
Sop K-res
1150060-1 M2 >32 >4 >16 ESBL Positiv aac(6`)-Ib-cr Positiv
512 2 6
51 96 24 96 2 8
52 6 16 8 2 6




49 32 16 128 1 12
45 48 32 4 2 12 48
46 48 8 128 1,5 12 24







54 256 16 768 1,5 24 24
53 48 4
55 32 3 4 0,75 4




















59 24 24 6 3
62 24 3 4 0,5
8
63 128 32 128 4
64 0,38 32
3212
3 2 0,5 4
66 96 12 512 0,75







67 64 >256 256





















71 96 12 128 1
74 12 16 32 0,5
48
75 96 12 6 1
76 48 48
1616
48 96 4 24
78 48 12 192 1,5







79 48 48 8







82 24 >256 4






















































APPENDIX 3: BLOOD CULTURE 
ECOFF/R ≤2/≥8 ≤8/≥32 ≤16/≥64 ≤8/≥32 ≤2/≥8 ≤2/≥8
















1106372-3 R R Positiv
E.Coli
1192505-4 R I Positiv
G.st
1021892-2 R R Positiv aac(6`)-Ib-cr Positiv
E.Coli
1035306-1 R R Positiv
E.Coli
1046926-4 R R Positiv
Klebs-pn sp.pn
106334-1 R S Positiv aac(6`)-Ib
E.Coli
1077578-1 R R Positiv
E.Coli
1113212-4 R R Positiv
E.Coli
1155560-1 R R Positiv
E.Coli
1015406-1 R R Positiv
Klebs.pneum 
spp.pneum




1070048-1 R I Positiv
E.Coli
1070152-1 R R Positiv aac(6`)-Ib-cr Positiv
E.Coli
1096687-1 R R Positiv aac(6`)-Ib-cr Positiv
E.Coli
1097110-1 R R Positiv
E.Coli
1131676-1 R R Positiv aac(6`)-Ib Positiv
E.Coli
1192781-4 R R Positiv
E.Coli
1016115-1 R R Positiv
E.Coli
1025243-2 R R Positiv
E.Coli
1034974-1 R S Positiv
E.Coli 128
1041884-1 R R Positiv
E.Coli
1058151-1 R R Positiv
E.Coli
1066678-1 R R Positiv aac(6`)-Ib-cr Positiv
E.Coli
1104063-1 R R Positiv
E.Coli
1175173-1 R R Positiv
E.Coli





8 2 12 2 0,75 0,75 I S G-----
E.Coli
1085238-3 R R Positiv
E.Coli
1095499-3 R R Positiv aac(6`)-Ib Positiv
16 GKS-NT40 >256 192 384 3 24
37 8 32 32 16 GKs—T
39 >256 12 16 3 12 8 Gk—NT
3 1
16 GkS-NT
36 192 16 8 3 6
34 >256 16 24 3 12 24 Gks-NT
8 Gk—nT
35 >256 16 192 3 12
Gk—NT
31 256 12 2 12 12
8 4 12





12 >1024 3 GkS-NT
30 256 16 8 3 12
12
27 >256 12 6 2 8 8
8256
Gk—NT
28 >256 24 384 3-4 12 12 GkS-NT
12 GkS-NT
23 256 96 16 16 24
24 GKS-NT
32 GK-aNT
24 >256 24 512 3 12
26 >256 >256 >1024 4 16
21 96 8 12 2 6 6 G---nt
22 96 128 96 8 16 32-48 GKS-NT
19 64 48 128 4 8 24 GKS-NT
20 1 3 192 2 0,75 0,75 --S---
17 256 16 128 3 12 12 GkS-NT
18 >256 12 256 3 16 12 GkS-NT
15 96 6 16 2 32 12 G---NT
16 96 8 16 3 16 6 G---Nt
13 256 24 384 3 16 12 GkS-NT
14 48 256 96 3 12 256 GKS-NT
11 256 256 16 12 32 96 GK-aNT
12 256 24 128 3 12 12 GkS-NT
8 256 16 96 2 8 12 GkS-NT
10 256 32 32 3 48 16 GKs-NT
5 1,5 4 12 4 1 1,5 ------
7 64 12 >1024 4 48 256 GkS-NT
3 1 3 >384 3 1 1 --S---
4 64 256 >1024 12 32 64 GKSaNT
1 256 16 6 2 24 16 Gk-- NT







APPENDIX 4: BLOOD CULTURE 
ECOFF/R ≤2/≥8 ≤8/≥32 ≤16/≥64 ≤8/≥32 ≤2/≥8 ≤2/≥8




1100411-1 R R Positiv
E.Coli
1104939-1 R R Positiv
KPNPN
1126222-2 R R Positiv
Klebs




1156514-1 R R Positiv
E.coli
1167080-1 R R Positiv
E.coli
1188153-1 R R Positiv aac(6`)-Ib-cr Positiv
KPNPN
1190037-1 R R Positiv aac(6`)-Ib-cr Positiv
E.coli
1018391-1 R R Positiv
E.coli
1020811-1 R R Positiv aac(6`)-Ib-cr Positiv
E.coli






42 >256 24 384 3 16 12 GkS-NT
41 >256 12 96 3 12
12 GK-aNT
44 32 64 8 12 24 12 Gk-aNT
43 48 64 6 12 12
2 g-----
46 >256 32 256 3 16 16 GKS-NT
45 6 3 12 2 1,5
12 GkS-nT
48 64 64 16 6 8 32 GK—NT
47 >256 16 384 3 6
32 GKS-NT
50 >256 16 256 2 12 8 GkS-NT
49 >256 >256 512 8 24
1 --S---53 0,5 2 128 1,5 0,75
48 GK—NT
52 >256 16 12 3 8 12 Gk—NT
























Sequences found matching the genes aac(6`)-Ib and aac(6`)-Ib-cr when the SNP`s responsible for the amino 
acid substitutions Trp102Arg and Asp179Tyr.  Escherichia coli strain IncA/C2 plasmid GQ293500.1Escherichia coli strain IncA/C2 plasmid GQ293499.1Escherichia coli class I integron integrase (intI) gene AY152821.1Escherichia coli strain nb018 GQ214316.1Escherichia coli plasmid pKO97 AY878717.1Escherichia coli strain 2098EC FJ619242.1Escherichia coli strain 2039EC FJ619241.1Escherichia coli strain 1387 plasmid pHS1387 class 1 integron EU675686.2
aac(6`)-Ib GenBank number 
 
 
 Escherichia coli plasmid pEK516, complete sequence NC_013121.1Escherichia coli strain D plasmid pEK516 EU935738.1Escherichia coli plasmid pHSH2 encoded class 1 integron In37 AY259086.1Escherichia coli strain 2073EC FJ829034.1Escherichia coli strain MS12 EU279426.1Escherichia coli strain CQ4 EF571008.1
aac(6`)-Ib-cr


















Map over variations: 
 
 The Query sequence used was the FASTA sequence from Escherichia coli strain 2098EC (GenBank 
number: FJ619242). The search was performed in the nucleotide selection among Enterobacteriaceae 














The yellow areas are variations in bases detected, manually marked in the sequence. The green illustrate the 
SNP`s in focus that cause this sequence to encode AAC(6`)-Ib. If T was C and G was T it would have been a 
sequence encoding AAC(6`)-Ib-cr. The underlined areas illustrate the primer and probe sequences used. One 
variation was detected in one of the primers, with the consequent risk losing its specificity. This was solved by 
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